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Abstract 
Generation of deeply inspirable clouds from dry powder mixtures 
Dry powder aerosols are widely accepted as an effective means of 
drug delivery to the lungs. They are generally formulated by mixing 
the cohesive, micronised drug with larger carrier particles. 
Redispersion of the drug particles from agglomerates or carrier 
surface during inhalation is the most critical factor which governs 
the availability of the medicament to the lungs. This will depend on 
the mechanical stability of the powder mix and the way this is 
influenced by the adhesion characteristics between the drug and 
the carrier and the external forces required to break up the bonds 
formed between adhering particles. 
The external forces are provided by two components: the 
inspiratory flow rate and the turbulance created within the inhaler 
as air flows through it. 
To study the influence of inspiratory flow rate an apparatus was 
developed to permit physical characterisation of an aerosol cloud 
generated at flow rates ranging between 60-2001/min, employing 
the principle of isokinetic sampling to collect a representative 
fraction of the generated aerosol. Isokinetic conditions were 
verified using laser doppler anemometry. 
The effect of turbulence on the characteristics of an inspirable 
cloud was investigated and an inhaler was designed to provide high 
levels of turbulence with minimum resistance to air flow thus 
resulting in efficient de-aggregation of the powder components and 
allowing the patient to inhale with minimum effort. 
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The characteristics of an inspirable cloud were found to be highly 
dependent on the carrier surface properties, the particle size of 
both the drug and the carrier, the presence of ternary components 
in the mix, the drug to carrier ratio and the nature of the 
electostatic charges induced on the powder component. 
Since the carrier surface properties were found to be of great 
importance, modification of the surface of lactose was undertaken 
to produce a carrier with a low surface rugosity. A great increase in 
the respirable dose was observed with the formulation comprising 
the modified carrier even at low air flow rates. 
Preliminary in vivo evaluation of the novel formulation and the 
new inhaler were performed by assessing the lung function of 
asthmatic patients before and after administration of the 
medicament. The novel formulation with a modified carrier was 
superior to a commercial formulation and the basic design of the 
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Airborne particles are present throughout the environment. They 
exist in many different forms, such as dusts, fumes, mists, smog, fog 
or smoke. These suspended microscopic particles are examples of 
aerosols. Inhalation is a primary route by which these foreign 
substances may enter the body and therefore airborne particles 
(aerosols) constitute a major cause of respiratory disease. 
However, other types of aerosols are being used increasingly in a 
beneficial role for the assessment of lung structure and function 
and hence for diagnosis and, ultimately, the topical treatment of 
respiratory disorders. 
The administration of therapeutic agents to the large surface area 
of the bronchial tree by inhalation of airborne particles has the 
important advantage that the drug is applied close to the target 
tissue. As a result, the drug often begins to act very rapidly and 
dissipation of its effect due to pharmacokinetic factors is 
minimized. The effective dose is therefore small, with a reduction 
in the incidence of systemic side-effects. 
There is an increased interest in the inhalation route as a means of 
introducing pharmacological agents systemically providing that the 
drug in question is absorbed via the airways without being 
metabolised "(Newman & Clark1985) 
For better understanding of the aerosol behaviour this chapter will 
briefly review some aspects of lung physiology and anatomy and the 
major respiratory disorders and therapy. Aerosol deposition and 
generation as a means of drug delivery and the methods of their 
evaluation will be discussed. 
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1.1 The physiology of the respiratory tract 
The respiratory tract can be divided into three main zones: 
1. The upper airways which include the nasal passages, mouth, 
pharynx and larynx. Its main purpose is to conduct air, swallowing, 
air conditioning, smelling, speech and filtration. 
2. The tracheobronchial airways or conducting airways which 
comprise the trachea, the bronchi, the bronchioles and the terminal 
bronchioles. Its function is air conduction and filtration. 
3. The pulmonary region or the alveolated region where oxygen 
and carbon dioxide are exchanged between inspired air and the 
blood. 
A schematic representation of the human respiratory tract is shown 
in Figure 1.1. 
The lung divides dichotomously for about 23 generations until it 
reaches the alveolar sacs, which number approximately 300 million 
and cover some 70-80m2 in the average adult human lungs. 
Distributed over this surface is 80m1 of blood in the alveolar 
capillaries, through which oxygen is exchanged. Thus the 
respiratory bronchioles and alveoli provide the greater surface for 
absorption of the inhaled particles than the other parts of the 
respiratory tract. 
The airway walls consist of epithelium, smooth muscles, cartilage 
and glands in a framework of connective tissue (Hale et al, 1968). 
A series of horseshoe ring cartilages located in the tubular 
structure of the airways keeps the trachea open, this cartilagenous 
support in the walls decreases in size and gradually disappears as 
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the airways branch further. The last generation of small bronchi 
contains little cartilage, whereas the bronchioles are distinguished 
from the bronchi by the absence of cartilage. 
The epithelium of the airways is composed of ciliated and goblet 
cells, together with columner epithelial and basal cells. Situated 
between the basal membrane of the epithelium and the cartilage of 
larger airways are mucous glands, ducts of which open on to the 
epithelial surface. These glands are absent in bronchioles. The 
ciliated epithelium, the goblet cells and the glands are essential 
parts of the mucociliary clearance mechanism that help eliminate 
foreign matter from the lungs. 
The smooth muscle network is arranged in the airway walls to allow 
changes of width as well as of length. The amount of smooth 
muscle increases in the small bronchi and it occupies the largest 
fraction of the wall thickness in the terminal bronchioles. 
Secretory cells without cilia (Clara cells) occur in bronchioles and 
increase in number towards the terminal bronchioles and it is 
believed that they contribute to the production of surfactants. Mast 
cells are found around the airways and in the pleura of the human 
lungs. 
Nerve fibres, ganglia and possible sensory elements are present in 
the airway walls. The function of the nerves is primarily concerned 
with the efficient control of ventilation under varying conditions, 
and protection of the lung in terms of cough, bronchoconstriction 
and mucus secretions. The lower respiratory tract is innervated by 
the autonomic nervous system through branches of the vagus nerve 
and thoracic sympathetic ganglia. Parasympathetic vagal 





Fig 1.1 Schematic representation of the human respiratory tract 
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released from postganglionic nerve endings stimulate receptors on 
target cells. Cholinergic ganglia are found throughout the 
tracheobronchial tree and they have been established and studied 
in man (Nadel & Barnes;. 1984) 
The sympathetic innervation of human airways reaches the most 
peripheral parts. Two types of adrenoceptors have been 
demonstrated: alpha receptors, stimulation of which produces 
bronchoconstriction and beta receptors which are subdivided into 
B-1 and 8-2 receptors. 3-1-receptors are mainly present in the heart 
and they mediate cardiac stimulation. B2-receptors mediate 
smooth muscle relaxation in the bronchi and blood vessels. 
Circulating adrenaline released from the adrenal medulla activates 
alpha or beta adrenoceptors and produces bronchodilation because 
beta-receptors outnumber alpha receptors in the airway walls. 
1.1.1 Air flow through the respiratory tract 
The design of the respiratory tract is optimal so as to maximize 
alveolar ventilation and to minimize airflow resistance. 
Airflow dynamics in the tracheobronchial tree have been studied 
extensively employing models of the human airways. The nature of 
airflow within the respiratory tract is of great importance in 
determining the fate of inhaled particles. Flow dynamics in the 
human airways vary with the inspiratory flow rate and local airway 
geometry. Relatively high airflow velocities are normally present in 
the airways even in quiet breathing and airflow in the trachea and 
bronchi is turbulent atacertain stage during the breathing cycle. 
The constricted entrance of air to the trachea via the larynx 
increases the degree of turbulence. However, as air progresses 
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down the respiratory tract, the overall cross sectional area increases 
resulting in laminar flow beyond the first few generations. 
However, branching affects flow patterns and flow irregularities 
over several more generations are possible. 
In the pulmonary region, bulk flow is almost non-existent, relying 
primarily on gaseous diffusion. 
Variation in lung morphology and airway dimensions with aging 
and pathologic processes have been reported. Therefore, the local 
linear velocity of the air stream within the tracheobronchial tree 
will be determined by the airway anatomy and the inspiratory flow 
rate. 
Inspiratory flow rates in normal human adults can be as high as 
3001/min, whereas in a child or in certain disease states, flow rates 
are much lower. Recently, it was reported that patients with mild 
asthma can achieve a peak inspiratory flow rate of up to 200 1/min 
(Richardset a1,1987). 
1.2 Inhalation therapy for respiratory diseases 
Treatment of respiratory diseases by inhaled remedies is a form of 
therapy which has been used for many years in several parts of the 
world. Early methods involved primarily the inhalation of volatile 
aromatic substances with a mild irritant action, such as menthol, 
thymol and eucalyptus, or the inhalation of anticholinergic 
alkaloids derived from burning the leaves of plants such as Atropa 
belladonna and Datura stramonium. 
Nowadays inhalation therapy has, however, become the most 
widely used system for drug delivery in the management of both 
acute and chronic asthma (Shenfield & Paterson, 1973) . In addition, 
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inhalation therapy is used in the treatment of other obstructive 
airway diseases, such as chronic bronchitis. 
1.2.1 Respiratory diseases 
Asthma 
The word asthma(aao/Aa) is derived from a Greek word meaning 
difficulty in breathing. From a diagnostic point of view, asthma is a 
disease characterized by wide variations in resistance to airflow in 
pulmonary airways over short periodsof time (Scadding 1987). 
The pathophysiological features can be divided into muscle spasm, 
airway inflammation with oedema and mucous hypersecretion 
(Hogg, 1982). However, the relative importance of these 
abnormalities varies with the disease state. Spasm of the bronchial 
smooth muscles can occur rapidly in response to a provocative 
stimulus and can be easily and completely reversed by drugs that 
relax smooth muscles. Respiratory mucous accumulation and 
oedema formation are likely to require more time to develop. 
These disorders are usually the major cause of death in asthma 
since they might be irreversible. 
Chronic bronchitis and emphysema 
These are inter-related conditions normally referred to as chronic 
obstructive airway disease. The main clinical symptoms associated 
with these diseases are breathlessness accompanied by wheeze, 
cough and sputum. 
The mechanism of bronchial narrowing in these diseases differs 
from that in chronic asthma. It is mainly due to mucous gland 
hypertrophy in the bronchial epithelium, excessive mucous 
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production, and airway collapse resulting from abnormal 
enlargement of the gas-exchanging air spaces distal to the terminal 
bronchiole, thus interfering with the mechanism of blood 
oxygenation. 
The value of bronchodilator agents in these diseases is limited in 
comparison with their effect in bronchial asthma because the 
contribution of bronchospasm to ventilatory impairment is small 
compared with the effect of inflammatory changes in the bronchial 
mucosa and obstruction by excessive bronchial secretions. 
1.2.2 Drug treatment of respiratory diseases 
Bronchodilators 
Bronchodilators generally act rapidly to relieve bronchospasm. 
They can produce a substantial increase in pulmonary function by 
dilating the central and peripheral airways (McPhillips , 1985 ). 
They also appear to exert a prophylactic effect if taken on a regular 
basis (Paterson et al, 1979). Bronchodilator drugs classification can 
be thought of in terms of autonomic pharmacology of bronchial 
smooth muscles which provides a useful framework for 
understanding the wanted and unwanted effects of many of the 
most valuable bronchodilators. The wanted effect is the relaxation 
of the bronchial smooth muscles and subsequent bronchodilation. 
The unwanted effects arise from the action of these drugs on other 
receptors which produce different effects ( Table 1.1). 
1. Sympathetic bronchodilators 
ß-adrenergic agents are widely used as maintenance therapy in 
asthma and bronchitis. These compounds act by stimulating the 
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adrenergic receptors on smooth muscle cells in the airway walls, 
thus increasing the cellular concentration of cyclic AMP (cyclic 3', 
5' - adenosine monophosphate) which influences the activity of 
phosphokinase which, in turn, is responsible for further enzyme 
stimulation to give the final cellular activity, manifested by 
relaxation in the smooth muscle fibres and subsequent 
bronchodilation. Adrenaline was the first sympathomimetic agent 
to be used as a bronchodilator in 1910. Its chemical structure 
(Figure 1.2a) shows it to be a catecholamine. Adrenaline is 
ineffective when taken by mouth because it is largely inactivated by 
monoamine oxidase present in the gastrointestinal tract. In 
asthma, the usual routes of administration are by inhalationof a 
nebulised solution or by subcutaneous or intramuscular injection. 
This compound was followed by the introduction of isoprenaline 
(Figure 1.2b) in 1940. The structural changes of isoprenaline alters 
the pharmacological properties to almost exclusive ß-receptor 
activity. This compound is administered mainly by inhalation from 
metered dose inhalers or from nebulisers, since it is almost 
ineffective when administered orally due to enzymatic conjugation 
to an inactive sulphate derivative during its passage of the gut wall 
Figure (1.3). Intravenous administration of this compound leads to 
the formation of 3-0-methyl isoprenaline due to its metabolism by 
catechol-o-methyl transferase (COMT). The resulting compound is 
active, but due to its non-selectivity at the 13-receptors, its use is 
limited by the cardiovascular side-effects. Therefore, the 
inhalation route is preferred since it appears to provide adequate 




"Autonomic" classification of bronchodilator drugs 
Autonomic action Drug Nature of action and 
unwanted effects 
Sympathetic (Adrenergic) Adrenaline Relaxation of bronchial 
Ephedrine smooth muscle (ß2-effect) 
Unwanted alpha and beta-1 
effects such as 
hypertension, tachycardia, 
cardiac arrhythnzias, headache, 
palpitation and tremor. 
Isoprenaline B2-bronchodilation. 
orciprenaline Unwanted B-1 effects such 
Isoetherine as palpitation, tachycardia, 
headache and skin flushing 
Selective 132 132-bronchodilation 
sympathomimetics Unwanted ß2-effects 
such as terbutaline for instance 
and salbutamol) muscle tremor and 
tachycardia 
Anticholinergic Drugs Atropine Bronchodilation due to 
Ipratropium para-sympathatic blockade. 
bromide Unwanted effects such as 
dry mouth and airways 
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In 1960's, a rise in asthma mortality associated with the increasing 
use of bronchodilator aerosols was observed (Speizer et al, 1968). 
Although the actual cause has not been identified, tolerance to the 
effect of isoprenaline has been described in animals and humans, 
(Conolly et al, 1971). Cross-tolerance between B-receptor 
stimulants is a recognized phenomenon, leading to the possibility 
that B-receptor desensitisation due to tolerance from excessive use 
of B-adrenergic stimulants in patients with asthma might upset a 
hypothetical balance between constrictor and dilator influences on 
bronchomotor tone and thus aggrevate bronchoconstriction (Benoyet 
al, 1975). Thus, there was great awareness of the potential danger 
of sympathomimetics after this epidemiological evidence. 
The use of isoprenaline aerosols has declined since the 
introduction of the selective 132-sympathomimetic bronchodilators 
(Woolcock 
, 1977). These compounds offer a longer duration of 
action and fewer cardiovascular side-effects. ß2-sympathomimetic 
bronchodilators have the same basic structure as isoprenaline with 
alteration of the aromatic hydroxyl group which prolongs the 
duration of action. Additionally, substitution on the amine head 
provides greater 132-selectivity Figure (1.2c, d, e). Therefore, 
cardiovascular side-effects are reduced, although skeletal muscle 
tremor is sometimes observed. These drugs can be administered 
either orally or by inhalation. However, the inhalation route is 
preferable since it increases the therapeutic index by permitting a 
reduction in the total dose of drug administered while maintaining 
a useful bronchodilator effect. Bronchodilators delivered from 
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micrograms, of which only about 10% reaches the lungs, whereas a 
comparable oral dose would be of few milligrams (Larson & Svedmyr, 
1977). Heel et al( 1978) found that a higher incidence of side 
effects was associated with the oral administration of fenoterol than 
when a drug was given by inhalation. Inhaled bronchodilators 
produce a noticeable effect almost immediately and a peak effect 
after 15-30 minutes (Hetzel & Clark, 1976); whereas the same drugs 
given orally do not reach peak effect for 2-3 hours (Clark, 1979). 
Similar duration of action was obtained for these bronchodilators 
whether given orally or by inhalation. Bronchodilators 
administered intravenously have a rapid onset of action, but 
compared to inhalation they lead to high incidence of systemic side 
effects (Paterson et at, 1979). However (Hetzel'& Claik; -1977)`,, found 
that a 100-200µg inhaled salbutamol can give the same peak 
bronchodilation effect as 250µg intravenously, and additionally the 
aerosol has a longer duration of action. 
2. Anticholinergic bronchodilators 
Bronchodilation may be achieved by blocking the muscarinic action 
of acetylcholine. Pharmacological studies using atropine as a 
parasympathetic blocking agent in patients with asthma and 
obstructive lung diseases have confirmed the importance of 
parasympathetic pathways (Yu et al, 1972). However, the 
intolerable side-effects of atropine make it impractical to use. 
Recently, a synthetic anticholinergic agent ipratropium bromide, 
has been developed. This compound is a quaternary isopropyl- 
substituted derivative of atropine (Figure 1.4), and is said to have 
some degree of bronchoselectivity particularly when administered 
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b. Ipratropium bromide 
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by the inhalation route (Deckers , 1975). 
Oral absorption of this 
compound is poor, which tends to reduce the likelihood of side-effects 
arising from the swallowed portion of the aerosol dose. Ipratropium 
bromide has none of the undesirable CNS effects of atropine. The 
onset of action is somewhat slower than the selective ß . 2- 
sympathomimetic agents, but the duration of action is as long or even 
longer. Until recently this drug did not appear to have any advantage 
over the selective B 2agonists but studies have shown that in chronic 
bronchitis, ipratropium bromide (80pg) has a comparable 
bronchodilator effect to salbutamol (200µg) (Douglas et al, 1979). 
3. Methyl xanthines - 
These agents such as aminophylline and theophylline have proved 
to be potent bronchodilators. The mechanism by which they relax 
the bronchial smooth muscle is unknown. However, one possible 
explanation might be the inhibition of the enzyme 
phosphodiesterase, which cleaves c-AMP, thus resulting in an 
intracellular accumulation of c-AMP. These compounds are 
usually administered either orally or intravenously. As aerosols they 
have been found to have less bronchodilat, or effect than fi- 
agonists, and their bitter taste and the narrow therapeutic index 
make it difficult to formulate these drugs for inhalation. 
Sodium cromoglycate (SCG) 
Cromolyn sodium (disodium cromoglycate) is a prophylactic 
antihmatic agent which has been widely used in Britain since 
1968. Structure-activity correlation studies based on Khellin, a 
naturally occurring substance in a plant Anmmi Visnega, with 
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muscle relaxing properties, led to the synthesis of the bis-cromone 
cromolyn sodium (Figure 1.5). 
The precise mode of action of cromolyn sodium is still unclear, 
although the drug is known to inhibit the release of secretory 
granules containing chemical mediators such as histamine and SRS 
(slow releasing substances of anaphylaxis) from mast cells 
following antigen challenge of tissues sensitised with specific IgE- 
antibodies, which initiate the asthmatic reaction (Brompton 
Hospital Medical Research Council Collaborative Trial, 1972). 
Forman and Garland (1976) have suggested that this mechanism 
might occur by preventing calcium ion transport across the mast 
cell membrane which is necessary for mediator release from the 
cell. 
The oral absorption of SCG is poor (Walker et at, 1972), therefore 
administration via the respiratory tract is necessary for its action on 
the airway mucosa. Powder inhalers were developed for its 
administration (Bell et al, 1971). Metered dose inhalers and 
nebulizers have also been used. 
The major application of cromolyn sodium is a prophylactic 
treatment of asthma induced by exercise (Davies , 1968) or specific 
allergens. Studies have shown that sodium cromoglycate provides 
effective control of asthma in 65-75% of patients (Godfrey et al, 
1975). However, it has no bronchodilator action, and therefore it is 
not used in the management of acute attacks of asthma. 
Corticosteroids 
Corticosteroids are added to the therapeutic regimen of asthmatics 
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improve pulmonary function. Corticosteroids are used in the 
management of acute and chronic asthma. It is believed that these 
compounds probably act by decreasing airway resistance via an 
antiinflammatory effect. Systemic treatment with corticosteroids is 
associated with suppression of the hypothalamic-pituitary-adrenal 
axis. This serious side effect is related to some extent to the high 
dosage administered. Inhaled corticosteroids given in smaller 
doses may significantly reduce the undesirable effects and still 
control the symptoms of asthma. However, oropharyngeal 
candidiasis and hoarseness have been observed in few patients. 
Antibiotics 
Because respiratory diseases are often accompanied by chest 
infections, antibiotics are often prescribed. The use of antibiotic 
aerosols began in 1940. Aerosolized penicillin was used in the 
treatment of cystic fibrosis, and some short term benefit was noted 
(Agnese & Anderson, 1946). Rose et al (1970) used colistin aerosol in 
patients with chronic bronchopulmonary disease with gram- 
negative organisms in their sputum and a significant reduction in 
the sputum bacterial count was reported. Recently many studies 
have been conducted using nebulized carbenicillin, gentamicin, 
tobramycin and ceftazidime in the treatment of patients chronically 
infected with P. aeruginosa (Hodson, 1988). Renewed interest in 
the drug pentamidine has led to its widespread application in 
aerosol form to treat and prevent Pneumocystis carinii pneumonia 
in immunosupressed patients. 
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Water and saline aerosols 
These are often used in an attempt to liquify secretions and 
enhance their removal from the lungs post operatively, or to 
mobilize tenacious secretions in patients with chronic respiratory 
diseases. 
1.2.3 Inhalation therapy for systemic diseases 
The use of aerosols to deliver drugs for systemic therapy would 
appear to offer many advantages over other routes of systemic 
administration. The enormous surface area of the lungs provides a 
vast capillary interface for the absorption of substances that can 
penetrate into the alveolar region. A study of the use of 
ergotamine tartrate in the management of recurrent vascular 
headaches revealed that the average onset of response for patients 
taking oral tablets was 1V to 3 hours, whereas the response to oral 
inhalation in the same individual ranged between 10 to 30 minutes 
(Speed, 1960). 
Additionally, the constant pH and the nature of the enzymes in the 
respiratory region, all provide a good possibility for drug 
absorption, and reduce the extent of drug degradation or 
inactivation by the degradative enzymes in the liver and GIT 
(Gonda et al, 1978). 
Metabolic reactions can take place in the lung. These include: 
hydrolysis, o-methylation and mixed function oxidation. However, 
the metabolic pathway in the airways differs qualitatively and 
quantitatively from that of orally and intravenously administered 
drugs. Additionally, the role of the pulmonary tissues in 
metabolizing aerosolised drugs is not yet clearly defined. 
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Heparin by inhalation is another drug which has been proposed for 
systemic anticoagulation (Jaques et al, 1976). Intrapulmonary 
heparin resulted in an anticoagulant effect for up to 14 days after 
inhalation of a single large dose. The peak anticoagulant effect was 
not observed until the next day. The lengthening of clotting time 
increased with dosage. Examination of the lungs, body fluids and 
tissues showed that heparin was cleared rapidly from the lung and 
enters a body cellular compartment from which it is slowly released 
to plasma. No evidence was found of haemorrhage or any heparin- 
related pathological change indicating either immediate or long- 
term toxic effects in the lung or other tissues. 
Insulin, prepared as metered dose inhaler and inhaled by rabbits 
exhibited rapid peak plasma concentration after absorption from 
the lungs (Jones et al, 1988). 
Administration of these two compounds via the inhalation route 
offer the potential advantages of simple and apparently safe route 
of administration. Additionally, the inhalation route might have a 
potential in administering other peptides which are decomposed in 
the GIT if administered orally. 
Given these advantages, it may seem surprising, that the availability 
of systemic inhaled products is very limited. This reflects the fact 
that the progress in this field has not reached a point where an 
accurate dose of the drug can be specifically "targeted" to an 
absorption site in the lung. The limiting factors controlling accurate 
delivery of drug particles into the lower respiratory tract include 
the physiological factors related to the patient, the physical 
properties of the aerosol and the efficiency of the inhalation 
delivery systems. These factors are further discussed below. 
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1.3 Deposition mechanisms of inhaled particles 
Deposition is a process by which inhaled particles carried in an air 
stream separate from the flow streamlines and contact a respiratory 
tract surface from which there is no rebound or resuspension . 
Particles which remain suspended in the tidal air throughout the 
respiratory cycle are exhaled. 
Due to the anatomy and physiology of the respiratory tract, 
particles deposit at various sites within the bronchial tree by several 
mechanisms. Figure 1.6 illustrates the five possible mechanisms by 
which significant deposition might occur: impaction, sedimentation, 
diffusion, interception and electrostatic precipitation. However, 
the first two are the predominant deposition mechanisms in most 
cases. 
1.3.1 Impaction 
The inhaled air follows a tortuous path through the branching 
airways. Each time the air changes direction, the momentum of 
particles carried by the air stream tends to keep them on their 
established trajectories, which can cause them to impact on airway 
surfaces. 
If a particle is moving at a velocity, V, in the absence of gravity, the 
drag forces will bring it to a stop. Thus the trajectory motion of the 
particle is a balance between the inertial and resistant forces. The 
resistant force is given by Stoke's law, and a `stop distance' x, can be 
calculated. 
X=V. V_ (1.1) 
g 
where Vt is the settling velocity and g is the gravitational constant. 
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The aerosol particle will have a velocity of magnitude u sin e as it 
changes its direction by an angle B. Hence the particle moves a 
total distance of: 
X= (u sin a) Vt 
g 
(i. 2) 
For a particle travelling in an airway, the stop distance x can be 
compared with the radius, R of the airway. A dimensionless 
function, the Stoke's number (Stk) is related to the probability of 
deposition by impaction, where 
Stk = Pd2V (1.3) 
18 gR 
P is the particle density 
d is the particle diameter 
V is the air velocity 
' is the air viscosity 
R is the airway radius 
The higher the value of Stoke's number, the more readily particles 
will diverge from the airflow streamlines. Therefore, with large 
particles whenever the convective airflow is fast or turbulent as in 
the upper airways, or changing direction at bifurcations between 
successive airway generations, deposition by impaction is the most 
likely mechanism forming "hot spots" particularly on the carinal 
ridges of bifurcations. Consequently, this mechanism causes the 
major portion of aerosol deposition on mass basis. 
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1.3.2 Sedimentation 
This mechanism of deposition is a time dependant process, in 
which small airborne particles settle in airways under the influence 
of gravity, during either breath-holding or slow tidal breathing. 
Due to gravity, an airborne particle with density (Pp) greater than 
that of air (Pa) experiences a downward force (F) given by: 
F= v(PP Pa)g (1.4) 
where v is the volume of the particle. The particle accelerates 
downwards and reaches its terminal velocity when the retarding 
force due to is motion through the air just balances its weight. For 
a spherical particle Stoke's law can be used to predict the retarding 
force Fr : 
Fr = 3rdnV (1.5) 
where V is the velocity of the particle. 
At terminal velocity, Vt, the downward force is equal to the 
retarding force, therefore: 
Vt = (Pp Pa)d2 g 
1817 
(1.6) 
Stoke's law is valid for unit density particles of 1 to 40, &m in 
diameter settling in air. Correction factors can be included to 
extend the useful range for particles 0.001 to 200µm in diameter 
(Mercer 1973). For particles of large diameter, the retarding force 
is increased by the inertial effects of accelerating a mass of gas to 
push it aside. With a small diameter particle, the retarding force is 
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less than that predicted by Stoke's law because the particle is 
comparable in size to the mean free path of air molecules and can 
slip between molecules. 
Deposition by sedimentation takes place mainly in the small airways 
and alveolar spaces where the rapid increase in the cross sectional 
area gives low air velocity, and where large particles will rarely 
penetrate. 
1.3.3 Diffusion 
When the terminal velocity of the particles falls below 0.001 
cm/sec, which for unit density spheres is equivalent to the 
diameter of -0.5µm, deposition by diffusion becomes more 
effective than sedimentation. 
Particles less than one micrometer in size undergo a random 
motion in air caused by the impact of gas molecules. This 
brownian motion increases with decreasing particle size, and 
becomes an effective mechanism for particle deposition in the lung 
as the root mean square displacement approaches the size of the 
airspace. 
The root-mean square displacement(o)is given by: 
'6Dt (1.7) 
where 
t is the time 
D is the diffusion coefficient of the particles which can be 
expressed as, 




K is the Boltzmann constant 
T is the absolute temperature 
.' is the gas viscosity 
d is the particle diameter 
This mechanism is therefore, important for submicron particles. 
However, therapeutic aerosols are usually of larger sizes and this 
mechanism is responsible for only a small percentage of total lung 
deposition. 
1.3.4 Interception 
This mechanism is usually significant only for fibrous particles. It 
occurs when the trajectory of a particle brings it close enough to the 
airway wall so that the edge contacts the surface even though the 
particle's centre of gravity might lie in the convective air streamline 
relatively distant from the wall. 
1.3.5 Electrostatic forces 
Deposition of particles with high electrical mobility results from 
image charges induced on the surfaces of the airways'(Chan & Yu, 
1982 ). Particles produced by high velocity dispersion of solid or 
liquid material can have substantial electric mobilities (John 1980), 
and if their generation is followed immediately by inhalation before 
the rapid neutralization in the atmosphere, this mechanism might 
contribute considerably to aerosol deposition. 
1.4 Factors affecting deposition 







Fig 1.6 Mechanisms of particle deposition in 
respiratory tract airways 
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The deposition pattern of the inspired aerosol can be influenced by 
two major factors: 
1.4.1 Physiological factors 
The anatomical structure of the respiratory tract along with the 
mode of inhalation plays a significant role in the determination of the 
deposition mechanism of inhaled particles. The most important 
features of inhalation are the flow rate, the inhaled volume and the 
breath-holding time after inhalation (Newman et at , 1983). At 
high inspiratory flow rates, drug penetration into the lungs will be 
minimal due to the impaction of particles in the throat and the 
proximal part of the tracheobronchial tree. 
Newman et at (1981,1982), studied the response to a dose of a 
bronchodilator and the pattern of deposition as assessed by 
radioactive tracer techniques following carefully controlled and 
systematically varied inhalation manoeuvers from a pressurized 
metered dose inhaler. The studies demonstrated that metered dose 
aerosols should be inhaled slowly and steadily at about 301/min. 
Faster inhalation of approximately 801/min is less effective since 
more aerosol impacts in the oropharynx and is unable to penetrate 
into the lungs. Other workers have confirmed the value of inhaling 
slowly. Lawford and McKenzie (1981) found a greater bronchodilator 
response to fenoterol in a metered dose inhaler (MDI) following 
inhalation at 641/min than that at 1921/min. 
There are different opinions as to the point in the inspiratory 
process at which actuation of a metered dose inhaler should occur. 
Riley et all (1976,1979) found that an isoprenaline MDI was more 
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effective when actuated at a high lung volume i. e 80% vital capacity 
(VC) compared to low lung volume, 20% VC. However Newman 
et al (1981,1982) in a study carried out with terbutaline sulphate 
indicated that, provided the inhaler was activated during 
inspiration, no difference in efficacy was observed as a function of 
the point in the inspiratory phase at which actuation took place. 
The variations in the results may be attributed to the difference 
between the two studies. Riley et al performed their study on 
patients with mild airflow obstruction and used a very slow 
inhalation flow rate whereas Newman et al performed their study at 
higher flow rates. 
A period of breath-holding after inhalation increases the 
probability of peripheral deposition, since it allows time for the 
particles to settle on the airways by gravitational sedimentation. 
Several groups of workers have established that a period of 5 to 10 
seconds was found to enhance the clinical response and seemed 
both necessary and sufficient to give maximal bronchodilation. 
The correct mode of inhalation for powder inhalation aerosols was 
unclear until clinical studies showed that a higher response was 
attained at high inspiratory flow rates. In a study carried out using 
a fenoterol powder, there was a significant increase in response 
when children inhaled as fast as possible compared with very slow 
inhalation of 16-191/min. However, breath-holding pause of 10 
seconds after the inhalation had no significant effect on 
bronchodilation (Padersen and Steffensen, 1986). 
Auty et al(1987) examined the respiratory deposition of SCG as 
reflected by its plasma concentration and urinary excretion, and 
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found that a higher plasma concentration was achieved at high 
inspiratory flow rates and that a peak inspiratory flow rate around 
1601/min probably represented optimal inhalation rate. No direct 
link between plasma concentration and clinical effect was 
established in this study. 
However, the above observations were confirmed later by Richardset al 
(1988), who found that both inspiratory flow rate and the area under 
the plasma concentration time curve correlated well with the degree of 
protection afforded against AMP-induced bronchoconstriction. In this 
study, a link between inspiratory flow rate, plasma concentration and 
clinical effect was established. The increased protection at high 
inspiratory flow might be attributed to both an increase in the amount 
of drug delivered to the lungs and a more peripheral deposition. 
Marked differences in deposition between individuals were 
observed. The intersubject variability may be due to anatomical 
and physiological variation (Heyder et al, 1982). Pitchard et al 
(1986) demonstrated the difference in regional deposition of 
inhaled particles in the 2.5-7.5 um size range for a particular 
inspiratory flow rate between men and women. This difference was 
attributed to the dimensions of the airways and the size of the lung 
which varies with age, height and sex. 
Respiratory diseases influence the distribution of inhaled particles. 
Bronchoconstriction or obstruction of airways leads to diversion of 
flow to non-obstructed airways. The remaining healthy airways and 
alveoli may be increasingly exposed to inspired particles. 
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Narrowing of airways by muc -us, inflammation or bronchial 
constriction can increase linear airflow velocities, thus enhance 
inertial deposition and cause more central deposition patterns 
(Lourenco et al, 1972 and Lauber et al, 1986). Svartengren et al (1989) 
have reported that a small degree of bronchoconstriction induced in 
humans, can markedly diminish the fraction of alveolary deposited 
particles in the lung. 
1.4.2 Physical properties of aerosols 
The most important physical property influencing pulmonary 
deposition is the particle size of the aerosol cloud. Theoretically, 
inhalation aerosols may be targeted to a particular lung deposition site 
by governing the particle size. 
From equations 1.3 and 1.6, it can be seen that impaction and 
sedimentation depend on the product density-dianieter2 (Pd2). 
Therefore (Pd2) can be used to predict the deposition site and 
collection efficiency. The square root of this product is known as 
the aerodynamic diameter of the particle (Da). This diameter is 
used to describe the effective size of particles moving in an air stream 
(The Task Group on Lung Dynamics, 1966). It can be defined as the 
diameter of a unit density sphere with the same settling velocity as the 
particle in question (Agnew, 1984). 
Da =d P1/2 (1.9) 
Particle size may continually change throughout the duration of a 
breath. Volatile aerosols or water droplets may evaporate leaving 
smaller particulates. Conversely, hygroscopic materials may grow 
dramatically in size as they pass from ambient relative humidity to 
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greater than 99% RH in the respiratory tract, particularly if the 
particles are water soluble. Water will condense on the particle 
until the vapour pressure on the surface of the particle equals that 
of the surrounding air in the respiratory tract. This will result in 
the particle growing in size thereby altering the deposition pattern. 
This effect is of considerable practical importance since the 
majority of inhalation aerosols are hygroscopic to some extent. 
Lam et al (1984), pointed out that the particle size of inhaled 
salbutamol increased slightly during inspiration thus enhancing its 
deposition in the upper respiratory tract. Therefore the predicted dose 
of the drug that reaches the lower respiratory tract will be less than the 
non-hygroscopic aerosols of the same size. 
The importance of particle size in inhalation aerosols results from 
the ability of the different diameters and branching airways of the 
respiratory tract to act as an efficient size separator. Mathematical 
models have been proposed for calculating the extent of retention 
of particulate matter of various sizes in the average adult human 
lungs. A schematic representation of the theoretical deposition of 
particles in the pulmonary tree as computed by Landhal is shown in 
Figure 1.7 (Mitchell, 1960). 
The ideal size for therapeutic aerosols however is not known 
precisely. Davies et al (1976), estimated the size to be between 0.5- 
7.0jim. Particles larger than 7.0µm cannot penetrate beyond the 
trachea; whereas particles smaller than 0.5µm are probably 
exhaled. 
Curry et al (1975) found a greater response to sodium cromoglycate 
when administered in a size of 2.01jm compared with particle sizes 
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Trachea 
High collection efficiency 
for particles larger than 
60 microns, Tess than 1% 
for particles smaller than 
6 microns 
Secondary Bronchi 
Begins collecting particles 
as small as 2 microns 
Primary Bronchi 
Particles smaller than 2 microns 
foil to deposit in this region 
Respiratory Bronchiole ' 
Portides larger than 20 microns 
toil to reach this region 
Terminal Bronchi 
Particles smaller than O. E 
micron tail to deposit 
Iveolor Duct 
titres lorger'thon 6 microns 
to reach this portion of the 
tem; high collection effi- 
ncy for 2-micron particles 
Alveoli 
articles larger than 
microns toil to 
each this region 
Fig 1.7 Schematic representation of the theoretic deposition of 
particles in the pulmonary tree as computed by Landahl 
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of 6.0 and 11.7µm. This observation was confirmed by Rees et al 
(1982), who reported a greater bronchodilation response to 
terbutaline sulphate particles of diameter less than 5.0pm 
compared with inhaled particles in the size range of 5-10µm or 10- 
15pm. On the other hand, a similar deposition pattern was observed 
for 3.2pm and 6.4, radioactively labelled Teflon particles (Newman 
et al , 1984). 
Most aerosols are polydisperse and have a wide range of sizes. 
Because of the wide range and the fact that the physical properties 
of aerosols are strongly dependent on particle size, it is necessary to 
characterize these size distributions by statistical means. Distribution 
data are commonly plotted in a cummulative form (Figure 1.8). The 
geometric median diameter is the diameter corresponding to 50% on 
the plot such that 50% of all particles are above and below this value. 
If the cummulative curve is a straight line on the log-probability plot, 
the distribution is log-normal (Figure 1.9). The size range can be 
expressed by a geometric standard deviation (GSD) which is the 
diameter ratio at 84.1% and 50% or at 50% and 15.9%. This value is 
a measure of dispersity and corresponds to the standard deviation 
(± S. D. ) of the median diameter of the curve. The distribution pattern 
of deposited particles and the subsequent clinical response may be 
dependent on the fate of few particles carrying a high proportion of the 
total mass. It is therefore more appropriate to express these 
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1.5 Inhalation delivery systems 
For more than a century inhaled remedies were delivered to the 
respiratory airways by inhalation of hot aromatic vapours via reed 
pipes or by smoking cigarettes made from leaves of plants 
containing the therapeutic agent (Miller, 1973). 
However, in the modern era of aerosol therapy, three types of 
delivery system have been developed: nebulizers, pressurized 
metered dose inhalers (MDI) and dry powder inhalers 
(insufflators). 
For patient use the ideal aerosol delivery system should be easy to 
use, portable, unobtrusive, inexpensive and enable precise quantities of 
the medicament to be delivered directly to the lungs. 
1.5.1 Nebulizers 
The conversion of an aqeous solution into a mist of fine particles is 
a process known as nebulization. To achieve this process two types 
of nebulizers can be used: 
1. Jet nebulizers are the most commonly used nebulizers. They 
work on the Venturi principle. They are driven by gas, either air 
or oxygen, which is forced through a jet. This creates an area of 
low pressure which draws up the drug solution into the fast moving 
gas stream, where it breaks up into small droplets. Larger droplets 
are trapped on a baffle and fall back into the solution for 
renebulization. 
The major factor governing nebulizer performance is the flow of the 
compressed air used to generate the aerosol. Aerosol size is inversely 
proportional to the compressed gas flow rate (Davis SS 1978, Clay et 
al, 1983). 
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2. Ultrasonic nebulizers use high frequency sound waves 
produced from a piezoelectric transducer. The vibrations are 
focused on the surface of the liquid to generate the aerosol spray. 
A wide range of nebulizers is commercially available. However, 
the output and particle size varies considerably between the different 
types (Newman et al, 1986, Clay et al , 1983 and Ho, 1988). 
Nebulizers are flexible devices in that a wide range of medicaments 
may be administered. Large doses are normally dispensed by these 
devices, thus they are useful in acute severe attacks of asthma. 
However, nebulizers are the least portable of the inhalation devices. 
Therefore, they are mainly used for hospital treatment and 
increasingly in domiciliary use. Patients receiving this treatment, do, 
however, require comprehensive instructions regarding sterilization of 
the nebulizer, storage of the drug and maintainance of the compressor. 
1.5.2 Metered dose inhalers (MDIs) 
The introduction of MDIs over 30 years ago was a significant 
innovation in inhalation therapy. New medicaments have been 
introduced into this type of device in the meantime but the basic 
aerosol system has remained substantially the same. Preparations 
usually consist of solutions or suspensions of one or more active 
ingredients held under pressure in a suitable propellant or a mixture of 
propellants. Propellants, such as chlorofluorohydrocarbons, are 
liquified gases and mixtures of these may be used to obtain optimal 
solution properties and desirable pressure, delivery and spray 
characteristics. Pressurised inhalers may contain suitable auxiliary 
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substances such as solvents, solubilising agents, suspending agents and 
lubricating agents to prevent clogging of the valves (British 
Pharmacopoeia, 1988). They are intended to be inhaled in controlled 
amounts and are delivered by the actuation of an appropriate 
metering valve. 
The generated aerosol cloud contains drug particles in an envelope 
of surfactant or co-solvent and propellant. The size distribution of 
the emitted aerosol is not precisely known. Hiller et al (1978) 
noted that the size distribution of MDI aerosols does not 
necessarily conform to log-normal modelling and a multi-modal 
distribution was observed. In more recent work, Bouchikhi et al 
(1988) obtained a multi-modal distribution, however, a different 
aerodynamic profile was observed, which is a function of physico- 
chemical properties related to the formulation and the 
environmental conditions. 
On actuation of the MDI, rapid initial vaporization of the 
propellant occurs. This breaks up the liquid stream into filaments 
then droplets. The particle velocity exceeds the inspiratory flow 
rate, thus a large number of particles are impinged onto the 
oropharynx. A rapid cooling due to heat transfer during propellant 
evaporation promotes condensation of water vapour onto the 
droplets. The resultant particle size therefore might be larger than 
the micronized drug particles. The determination of size together 
with velocity is necessary for this type of aerosol, since both factors 
can affect lung penetration. MDIs are widely favoured since they are 
highly portable, inexpensive and represent a convenient method for 
multi-dose delivery. 
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However, there are many inherent disadvantages associated with these 
systems. Clinical research over the years has shown that there is an 
optimum way for the MDI to be used but it has become increasingly 
clear that a large proportion of patients do not employ this technique 
effectively. 
The most common problem is the inability to synchronise aerosol 
release with inspiration (Crompton, 19820 -To solve this problem, 
several inhalation aids have been developed. A spacer fitted to the 
mouthpiece of a conventional MDI is believed to cause a delay 
between actuation and inhalation thus reducing the need for co- 
ordination (Koing , 1985). 
Recently, a breath-actuated MDI 
(Aerolin Autohaler) was developed (Crompton , 1988. 
). This device 
requires minimum patient involvement to ensure that drug delivery is 
synchronous with inhalation. It is believed that the new inhaler 
functions reliably at inspired flow rates of around 281/min. 
A drawback of the MDI delivery system is their content of 
chlorofluorocarbon propellants. There has been some controversy 
about their toxicity, the possibility of causing bronchoconstriction 
and potential arrythmogenic effects 
(Thiessen & Pedersen, 1980). In 
addition, the use of these substances his 'been greatly criticized 
owing to the possible destruction of the ozone layer in the 
atmosphere (Maugh , 1984) and 
increasing the "green-house" effect. 
1.5.3 Dry powder inhalers 
Dry powder inhaler systems provide clear advantages over other 
delivery systems. Because of their convenience and portability, they 
are widely accepted by both patients and clinicians as an effective 
means of drug delivery to the lower respiratory tract. The clear 
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advantage of dry powder systems is that the inspirational effort of the 
patient leads to entrainment of the drug powder in the inhalation air 
stream. Therefore these devices can be of great importance, 
particularly to those who have difficulty in co-ordinating the actuation 
of MDI with the intake of breath (Crompton , 1982a). 
The product consists primarily of a device from which the drug 
powder is dispensed and a means of containment of the drug 
system. A balance between effective delivery of the medicament to 
the lower respiratory tract, and patient convenience and acceptability 
depends strongly on two elements: 
1. The formulation. 
2. The design of the device. 
The drug particles are presented in respirable fractions, i. e. 5pm or 
less in diameter. However, this involves problems of powder 
fluidisation, flow and dispersion. Additional complication may rise 
if a potent drug substance is to be used in doses of few micrograms. 
Therefore, an inert soluble carrier, commonly lactose, is included 
in the dry powder formulations to facilitate the fluidisation process. 
However, for the drug to penetrate into the respiratory tract, it has 
to be dispersed as single particles. In this respect the construction 
of the device affects the type of air flow within the inhaler air 
channels and the ability of the system to both empty the powder 
reservoir and redisperse the powder mixture as separate 
components. 
To describe the nature of airflow in the air channels, Reynold's Number 
can be employed. 
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Reynold's Number = dVP/r, 
where 
d is the tube diameter 
V is the air velocity 
P is the air density 
is the air viscosity 
The use of this dimensionless parameter allows the differentiation 
between laminar and turbulent flow and quantifies the level of 
turbulence in a tube. If Reynold's Number is greater than 2000, 
then the flow is turbulent. A value less than 2000 indicates laminar 
flow. 
Over the past two decades, particular emphasis has been given to 
the development and production of different powder inhaler devices. 
The first invention was the "Spinhaler" (Fisons Ltd)shown in Figure 
1.10a for inhalation of cromolyn sodium (Bell et al, 1971). In this 
design, a gelatin capsule containing the powder mixture is inserted into 
a rotor and pierced. As the patient inhales, the revolution of the rotor 
causes high-frequency vibration in the capsule wall. The powder is 
fluidised within the capsule and the vibrations cause the drug to be 
dispensed into the inhaled air stream through the perforations. 
In 1977, a new dry powder device the "Rotahaler"(Allen & Hanbury's 
Ltd) was introduced (Hallworth , 1977), initially for salbutamol 
(Duncan et al , 1977) and subsequently for beclomethasone 
dipropionate (Carmichael et al, 1978). The construction of this 
device (Fif 1.10b) is fairly simple compared to the "Spinhaler". The 
capsule "Rotacap" is inserted into the end of the inhaler. As one end 
is turned, the capsule is separated into two halves. The part 
containing the powder drops into a chamber and the drug particles are 
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dispensed into the air stream as the patient inhales through the device. 
In another powder inhaler, "Berotec" inhaler (Boehringer Ingelhiem), 
the drug is inhaled through the pierced holes of a stationery capsule 
contained in a very narrow chamber (Fig 3.10c). 
These devices are based on the inhalation of a pre-packed unit doses 
which are inserted into the device prior to inhalation. Reloading the 
inhaler can be very inconvenient to the patient especially in acute 
attacks of asthma. Therefore, over the last few years, new devices have 
been developed to improve the patient acceptability. In these 
improved delivery systems, the required dose is metered from a 
reservoir. 
The "Diskhaler" (Allen & Hanbury's Ltd) was designed to have 
similar efficiency to the "Rotahaler". In this reloadable device, a disc 
containing eight foil blisters of drug is inserted into the device. The 
inhaler is made ready for inhalation by lifting the mouthpiece cover. 
The blisters are pierced by means of a needle and the drug is dispensed 
into the inhaled air stream. The doses are numbered, making it 
possible for the patient to know how many doses remain. 
More recently, a multi-dose powder inhaler the 'Turbohaler" (Astra 
Pharmaceuticals) was introduced for administration of terbutaline 
sulphate (Figl. 10d). The "Turbohaler" is unique in that it is a metered 
dose inhaler which is not pressurized and is free from additives. The 
device is disposable after its 200 doses have been used and has visual 
warning signal when only 20 doses are left in the inhaler. The device 
is simply operated by twisting the turning grip at the bottom of the 
inhaler. The drug flows from a reservoir down onto a dosing disc with 
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Fig 1.10 
(a) Spinhaler (b) Rotahaler 
(c) Berotec inhaler (d) Turbohaler 
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fine holes. The holes are filled up and a metered dose is made 
available for inhalation as the inhalation air stream enters the channel 
into the dosing unit (Wetterlin , 1988). 
Encouraging results have been obtained in clinical trials performed 
to compare the efficiency and acceptability of these devices with other 
inhalation delivery systems. Dry powder inhalers seem to be more 
attractive and are now an established alternative to MDIs and 
nebulizers. 
1.6 Efficiency of inhalation delivery systems 
With the range of inhalation devices, a question may arise as to 
which of these delivery systems is superior in terms of the clinical 
response produced. For this purpose clinical studies were carried 
out comparing the performance of the available devices and 
investigating whether switching a patient to an alternative type of 
inhalation device would produce the same response. 
A comparison between nebulized salbutamol and salbutamol from 
a metered dose inhaler was performed by Jenkins et al (1987) who 
reported that there was no significant difference in the efficiency of 
the two delivery methods. 
In a more recent study comparing the effectiveness of equal doses 
of salbutamol administered by a nebulizer and by a "Rotahaler", it 
was observed that salbutamol inhaled via a "Rotahaler" is just as 
effective as the same dose inhaled from a nebulizer in producing 
bronchodilation. Furthermore, the "Rotacaps" offered an 
advantage of being more portable than a wet nebulizer (Assouffi & 
Hodson, 1989) 
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Other studies have been performed to investigate the efficiency of 
a dry powder inhaler in comparison with a pressurized MDI. It was 
found that the powder dose of salbutamol administered via a 
"Rotahaler" has to be doubled in order to produce the same 
response as that from the MDI (Hetzel et at, 1977 and Muittari et 
at, 1979). However, in recent investigation, an equal dose of 
ipratropium bromide inhaled via a pressurized MDI produced the 
same effect as when inhaled via a powder inhaler, "Atrovent" ( 
Boehringer Ingelheim) (Salorinne et at , 1988). A comparable 
clinical effect was also observed for terbutaline administered by a 
pressurized MDI and by a multi-dose powder inhaler the 
"Turbohaler" (Parsson et at, 1988). Both "Atrovent" inhaler and 
the "Turbohaler" appear to release the same amount of the 
respective drugs as the MDI, whereas, with the "Rotahaler" above, 
double the dose was required for equipotency. This suggests that 
the type of powder inhalation device and the nature of the powder 
formulation might have a great influence on the efficiency of 
powder aerosols. 
In a study in children, fenoterol administered by a powder inhalation 
device was found to be superior to that by an MDI (Chambers et at 
, 1980). The difference observed in this study was attributed to the 
incorrect inhalation technique used when inhaling from a MDI, which 
emphasises the importance of synchronization. 
A comparison between various powder inhalation devices was 
carried out by Vidgren et at (1987), who showed that the respirable 
fraction of SCG achieved from various devices was significantly 
different (Table 1.2). The difference was attributed to the construction 
of the device . In a more recent work Bogaard et al (1989), found no 
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significant difference in clinical response of terbutaline 
administered via a "Turbohaler" and an equipotent dose of 
salbutamol administered by a "Rotahaler" (Figure 1.11). The 
"Turbohaler" was superior in its ease of use since it is a multi-dose 
system and requires only a relatively low inhalation flow for 
activation such as 33 1/min which was proved to give a good 
response (Parsson et al, 1988), whereas it was observed that at flow 
rate of 301/min, there was barely any rotation of the capsule in the 
"Rotahaler" and emptying was erratic (Svedmyr et a1,1982). 
All the above studies confirm that there is probably little difference 
in the clinical efficiency between the various devices providing that 
they are handled correctly. Each type of the inhalation devices has its 
own advantages and disadvantages. Therefore, the choice of the 
device will mainly depend on the patient's disease state. For instance, 
nebulizer treatment can be ideal in acute severe asthmatic attacks 
where co-ordination of actuation with inhalation as required with 
MDIs might be difficult, or high inspiratory flow rates cannot be 
achieved to actuate a powder inhaler. On the other hand, for routine 
use, patient convenience and acceptability are important. Therefore, 
more portable devices seem to be more suitable. However, the 
availability of the various types of devices makes it possible for all 
patients to benefit from inhalation therapy which is superior to 
other therapeutic dosage forms in the treatment of lung diseases. 
1.7 Evaluation of inhalation aerosols 
There seems to be little doubt that therapeutic aerosols must reach 




Table 1.2 The mean fractional deposition of Tc - labelled particles 
of SCG following inhalation from four dry powder inhalers 
Fraction from the dose % 
Inhaler Lungs Upper Device 
airways 
Spinhaler 11.5 30.9 57.6 
I. S. F 16.4 44.0 39.6 
Berotec 16.0 59.0 25.0 
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Baseline Placebo 0.25.0.50 1.00.2.00 4.0 mg Terbutaline 
0.20 0.40 0.80 1.60 3.20 mg Salbutamol 
Fig 1.11 Mean cumulative dose-response curves following inhalation of 
terbutaline using a Turbohaler and salbutamol using a Rotahaler 
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principle that the light scattered by a particle is a direct function of its 
size. Davieset al (1980 a, b) employed the " Royco" particle size 
analyser which measures the projected area diameter of the particles 
and provides rapid counts of large number of particles. More recently 
laser Fraunhofer diffraction size analyserswere introducedwhich offer 
even more potential for rapid measurement. 
Aerodynamic size distribution can be measured employing the 
single particle aerodynamic relaxation time (SPART) analyser. In 
this technique particles are subjected to acoustic oscillation, and 
the aerodynamic diameter is directly related to the phase lag 
between particle oscillation and acoustic field oscillation (Hiller et 
al, 1978,1980). The limitations for the light scattering technique is 
that it requires extreme aerosol cloud dilution and thus large 
particles are lost and the initial droplet size changes during passage 
through the air before the measurement is made. This present 
problems of representative sampling. Additional limitations 
include lens aberration, background stray light and electric fields 
which can produce disturbances in the collection of signals. Using 
this method it is not possible to distinguish drug particles from 
foreign or excipient particles or from other drugs in combination 
drug products. 
One of the indirect methods which has been explored for sizing 
airborne particles is the one based on inertial separation. 
Impaction models which are intended to simulate the behaviour of the 
respiratory tract have been used (Kirk, 1972, ` Karig ei at, 1973 & Sciarra & Cutrie, 
1978) to compare the likely respiratory penetrability of aerosols. These 
models are very simple compared to the actual anatomical 
configuration of the human respiratory tract and give a poorly defined 
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size cut-off characteristics. 
Other impactors which have been developed basically for use in 
work places for collection and sizing airborne particulate matter to 
assess the potential health hazards from air contaminants have 
been employed for evaluation of therapeutic aerosols. Hallworth 
and Andrews (1976) used a number of conventional cascade 
impactors which utilise the relationship between velocity and mass. 
The value of this method is that a mass distribution of the aerosol is 
given directly in terms of aerodynamic diameter which describes 
the behaviour of inhaled particles within the respiratory tract. The 
quantity of collected materials in an impactor can be determined 
chemically or physically; a procedure which is time consuming. A 
simplified twin-impinger (Hallworth et al, 1978; Hallworth and 
Westmoreland, 1987) was subsequently developed for more rapid 
quality control processing of inhalation pharmaceuticals. This 
device is included in the British Pharmacopoeia (1988) as an 
official method for characterizing inhalation aerosols. The twin- 
impinger has proved to give a good correlation with the clinical 
performance of therapeutic aerosols (Padfield et a1,1983). 
Thus, the respirable fraction determined in vitro may vary depending 
on the technique used. Therefore, if any of these techniques gives the 
real respirable fraction can only be determined by referring to clinical 
trials. 
1.7.2 In Vivo methods: 
Deposition of therapeutic aerosols may be difficult to predict 
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accurately based on in vitro models. In vivo studies are essential to 
characterize the mode of deposition and hence the clinical response. 
For bronchodilators the simplest method for detecting the 
penetration of drug particles into the lungs is by assessing the lung 
function before and after administration of the medicament. 
Valuable information on the deposition of drugs in the respiratory 
tract may also be obtained from pharmacokinetic studies. The 
amount of drug and its metabolites in plasma and urine can be 
compared after both inhalation and oral intake (Walker et at, 1972 
and Fuller & Collier,. 1983) . 
Radioaerosol methods using gamma-ray emitting radionuclides are 
the most practical means of assessing both total and regional 
deposition of therapeutic aerosols. Inhaled gamma labelled particles 
can be detected externally by means of a gamma camera since 
gamma rays can penetrate the tissues of the body. Chemical labelling 
of antiasthmatic agents with gamma-ray emitting radionuclides is very 
difficult, since these compounds rarely contain an element with a 
suitable radionuclide. The only successful labelling achieved was with 
the bronchodilator ipratropium bromide-labelled with a gamma- 
emitter 77Br (Spiro et at, 1984). 
Inert labelled particles have been used as a model for the 
prediction of the deposition of inhaled particles. 99mTc has been 
found useful for labelling the inert materials. Teflon particles have 
been shown to be particularly suitable since they are biologically inert 
and insoluble in body fluids. Newman et at (1982) have studied the 
deposition of radioactive pressurized aerosols using these particles. 
More recently physical labelling of MDIs was achieved by the 
addition of 
99mTc to a canister containing the drug suspended in a 
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liquified propellant (Kohler et a1,1988 and Summers et al, 1989). In 
this technique the drug is not directly labelled but the distribution of 
the activity can be assumed to represent the distribution of the drug. 
Deposition from nebulizers were also studied using radiolabelled 
vehicles ( Clay et a1,1987) 
To assess deposition patterns from powder inhalation aerosols, two 
novel methods for physical labelling of the dry powder vwredeveloped. 
In the first method, Vidgren et al (198') labelled SCG particles using 
a spray drying technique. In the second method described recently by 
Newman et al (1989), the radionuclide 
99mTc dissolved in 
chloroform was added to a spheronized formulation of terbutaline 
sulphate and the chloroform was allowed to evaporate leaving 
radiolabelled particles. However, these two methods cannot be used 
to study deposition from all dry powder aerosols. Both spray drying 
and spheronization will change the physical properties of the drug 
particles and thus formulations containing mechanically micronized 
particles will have different inspirable characteristics. 
Therefore, until other techniques are available for labelling 
mechanically micronized particles which are normally present in the 
powder aerosols, direct detection of powder aerosols, within the lungs 
is not feasible and other in vivo techniques have to be employed. 
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1.8 Scope of the thesis 
The importance of inhalation, in particular that associated with dry 
powder inhalation, in the treatment of various respiratory diseases 
has been discussed in the preceding introduction. Studies on the 
major factors which influence the efficiency of powder inhalation 
aerosols are not well documented in the literature. The possible 
variables which might affect the fate and efficacy of the aerosol 
cloud in the respiratory tract are the formulation variables, the 
device and the patient (see Section 1.7). 
Recent clinical studies have shown that the patient's inspiratory 
flow rate is a major factor governing pulmonary deposition (Auty et 
al 1987, and Richard: et al, 1988). However, in vitro evaluation of 
dry powder inhalation aerosols in terms of inspiratory effort is not 
possible using the available techniques. The following work was 
structured under the following headings to study the efficiency of 
dry powder aerosols in relation to these variables: 
1. Development of an apparatus which permits physical 
characterisation of an aerosol cloud generated at various flow rates 
employing the principle of isokinetic sampling to collect a 
representative fraction of the generated aerosol. 
2. Assessment of the effect of formulation variables and a device 
on the characteristics of an inspirable cloud using the concept of 
mechanical stability of powder mixtures and the way this is influenced 
by factors which affect the adhesion properties between the drug and 
the carrier. 
3. In vivo evaluation of a novel dry powder aerosol formulation 
and a device. 
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Chapter two 
Design and evaluation of an apparatus for sampling 
and characterising an aerosol cloud 
2.1 Introduction 
In nature, solid particles such as dust are conveyed into the 
atmosphere as air flows over a layer of powder. At low air 
velocities, particles become detached from the surface and are 
carried by the turbulent air flow. However, at high flow velocities, 
not only the particles are carried away but the whole aggregates are 
torn out and disintegrated by the current of air (Fuchs, 1964). This 
is the principal mechanism by which dry powder inhalation aerosols 
are conveyed into the inhalation air stream of the patient. 
Aerosols produced by dry powder inhalers are polydisperse. As 
described in section 1.6.3, drug particles in the formulation are 
normally present in a respirable size together with a suitable carrier 
of a coarser size. Upon fluidisation, the aerosol cloud will consist 
of, a mixture of single fine drug particles, drug agglomerates of 
various sizes and coarse carrier with some drug particles still 
adhering to its surface. The size distribution of the generated cloud 
will mainly depend on the flow velocity of the air stream. This is in 
agreement with clinical studies which have indicated that the extent 
of pulmonary deposition is highly dependent on the inspiration rate 
(Auty et al, 1987, Richardset al, 1987, Dolovich et al, 1988). This, in 
turn, depends upon the patient's disease state and age. 
There have been no reports in the literature of in vitro studies 
carried out to predict the clinical performance of dry powder 
aerosols at flow rates exceeding 601/min despite the much higher 
inspiratory flow rates attainable by normal human lungs and even 
by mild asthmatics (Richard et al, 1987). 
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Previous workers (Bell et al, 1971, Chowhan et al, 1977, Hallworth & Westmoreland, 
1987, Vidgcen et al, 1987ýhave employed inertial separation methods to 
assess the physical characteristics of the whole aerosol cloud. 
However, although this technique has great relevance to the 
behaviour of the inhaled particles in the respiratory tract, the use of 
inertial impactors in this way is limited by their low operational 
flow speeds. Operating the impactors or impingers at different flow 
rates requires re-calibration of the impaction stages which 
fractionate the cloud. This process is very tedious and time 
consuming. Furthermore, operating the impactors at high flow 
rates may not be feasible, since increasing the suction flow rate 
within an impactor will increase the velocity within each stage. 
Solid particles will hit the impaction surfaces at a very high velocity 
and part of the kinetic energy of the particle will be dissipated and 
part is converted elastically to kinetic energy of rebound. If the 
rebound energy exceeds the adhesion energy, the particles will 
bounce away from the surface thus leading to errors in the particle 
size distribution. 
Similarly, operating the liquid impingers at high flow rates may 
cause severe rippling and excessive turbulence in the liquid as air 
impinges on its surface. Consequently, the liquid vortex shape and 
the jet liquid surface spacing will be inconsistent resulting in an 
inefficient particle size separation. 
Therefore, to study the behaviour of powder inhalation aerosols 
generated at various flow rates, there is a need to develop an 
apparatus which overcomes these difficulties. 
In occupational hygiene and environmental air monitoring, a wide 
72 
range of dust sampling configurations are employed for the 
determination of the concentration of airborne dust in a flowing air 
stream. In these dust samplers only a portion of the dust laden air 
is aspirated and collected by a measuring device. Therefore, a 
difficulty may arise in removing a sample which is representative of 
the gas stream. This can only be achieved if the velocity of 
aspiration into the sampling tube U, is equal to the free stream 
velocity Uo, at that point (Figure 2.1a). This is known as isokinetic 
sampling. 
Under isokinetic conditions there is no disturbance of the gas 
streamlines and the concentration of airborne particles inside the 
sampling tube will be the same as that in the undisturbed flow 
upstream. Failure to sample isokinetically (anisokinetic sampling) 
may result in distortion of the particle size distribution and 
misrepresentation of the concentration. Anisokinetic sampling 
occurs when the , sampling velocity differs from that of the gas 
stream. This will disturb the gas streamlines causing some particles 
to be deflected from their original direction of motion and hence 
the quantity of particles entering the sampling tube will differ from 
that entering under isokinetic conditions. The sample may contain 
either an excess or a deficiency of large particles depending on the 
conditions of sampling (see Figure 2.1c andd). 
Anisokinetic sampling might also occur if the sampling tube is not 
aligned with the gas flow streamlines (Figure 2.1 b). 
In the present study, the principle of isokinetic sampling was 
employed to develop an apparatus were a cloud generated at 
various flow rates, can be sampled isokinetically and fractionated 







a. Isokinetic sampling 
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entering probe 






b, Misalignment, e*0, c. U>Uo , d. U<UO 
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The guidelines for isokinetic sampling from a ducted aerosol flow are 
stipulated by Fissan et al (1987). However, sampling aerosols by 
this technique may cause many sampling errors as a result of 
aerosol transport to the site of analysis. 
This chapter discusses the development of sampling configurations 
and their suitability to isokinetic sampling. Aspiration efficiency, 
which refers to the effectiveness with which airborne particles are 
transported from the aerosol cloud outside the sampler and 
through the sampling tube, will be used as a means of evaluating 
the isokinetic sampling conditions. Additionally, flow visualization 
using laser doppler anemometry will be employed. 
2.2 Materials and methods 
2.2.1 Preparation of capsules 
Micronization of salbutamol sulphate 
Salbutamol sulphate was micronized using an air jet mill (Fryma 
Jet Mill, JM 80) at a powder feed rate of 5g/min and an air 
pressure of 7.5 bar. The moisture content was measured using an 
infra-red moisture balance at 100°C. The micronized drug was 
stored in a light resistant container in a vacuum desiccator over 
silica gel. 
Particle size analysis 
The particle size of the micronized drug was measured using 
scanning electron microscopy (SEM). The powder sample was 
mounted on the SEM stump and dispersed with a soft hair brush to 
break any agglomerates. Several photomicrographs were produced 
by scanning fields, selected randomly. The size was determined 
from the photomicrograph by tracing the perimeters of the 
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individual particles on a graphic tablet connected to a computer. A 
total of 500 particles were measured to obtain a size distribution. 
Classification of lactose 
Lactose monohydrate (Lactochem Pharmaceuticals) was classified 
into narrow size fractions. Air Alpine jet sieve was fitted with 
sieves to obtain size fractions of 125-180µm, 63-90µm and to give a 
powder all of which passed a 40µm mesh. This powder was 
classified into the range of particle sizes from 20-40pm, <20µm and 
< 10µm using a centrifugal air classifier (Alpine "zig-zag" classifier). 
The powder was dried in an oven overnight at 100°C. The powder 
samples were stored in a vacuum desiccator over silica gel. 
Preparation of powder mixtures 
Samples of drug-lactose were prepared in a ratio of 1: 67.5, 
according to the commercial "Ventolin" formulation, by mixing the 
micronized drug and the classified lactose with a spatula. The 
homogeneity of the mixtures was verified by the assay of ten 30mg 
samples by HPLC (see Section 2.2.2). 
Filling of the capsules 
Hard gelatin capsules (size 3) were filled with 27.4 ± 1.4mg of the 
powder mixture so that each capsule contained 400µg drug. The 
filling was performed manually. 
2.2.2 Development of an HPLC method for the determination of 
salbutamol sulphate 
The basic HPLC method employed for quantifying salbutamol 
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sulphate was provided by Glaxo, and used benzyl biphenyl as an 
internal standard, a mobile phase of 76: 24 v/v methanol and 
ammonium acetate solution (0.013M) and a reversed phase column 
packed with octadecylsilane. 
The following modifications were introduced: salmefamol was 
selected as an internal standard. It has a chemical structure similar 
to that of salbutamol (Figure 2.2) differing only in the substitution 
on the amine head. The longer hydrocarbon chain of salmefamol 
makes it less polar than salbutamol and thus, can be separated 
using a reversed phase chromatography. Therefore, modification 
of the mobile phase was essential for the separation. The revised 
mobile phase consisted of methanol and 0.013M ammonium 
acetate in a ratio of 65: 35 v/v. This provided the best peak 
separation of the drug and the internal standard. 
The HPLC system components 
The HPLC system consisted of the following: a pump, a multiple 
wavelength UV detector (Cecil instruments model C 2112), a 
reversed phase column (C-18 µ-Bondapack, 30cm x 3.9mm i. d), an 
integrator, a printer and an autosampler. 
HPLC conditions 
Flowrate: 0.8m1/min 
- Detector sensitivity: 0.02 AUF 
Detector wavelength: 276nm 
Injection volume: 40µl 
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Preparation of the internal standard solution 
Salmefamol was dissolved in the mobile phase to obtain a solution 
having a concentration of 0.0025mg/ml. This concentration gave a 
peak area ratio of drug to internal standard of 0.5-10. 
Preparation of the standard drug solutions 
An accurately weighed quantity of salbutamol sulphate (10.0mg) 
was transferred to a 100ml volumetric flask, dissolved in the 
internal standard 1 solution, and made up to volume to obtain a 
0.1mg/ml drug concentration. 
A 1,2,3,4,5 and 6m1 aliquot of this solution were pipetted into 
20m1 volumetric flasks and made up to volume using the internal 
standard solution. The mobile phase was pumped through the 
column. Injection of each of the standard solutionswas made in 
triplicate. The retention times for salbutamol sulphate and 
salmefamol were 4.7 and 5.8 minutes, respectively. A calibration 
curve was constructed by plotting peak area ratios of salbutamol to 
those of the internal standard versus salbutamol sulphate 
concentration. 
The developed HPLC method was reproducible and accurate with 
a standard deviation of +0.026 based on six consecutive injections. 
Determination of salbutamol sulphate content in powder mixtures 
The salbutamol sulphate content in the powder mixes was 
determined by accurately weighing a 30mg sample in a 20ml 
volumetric flask. The sample was dissolved in the internal standard 
solution. This solution was filtered through a millipore filter 
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was injected into the HPLC. No interference from the carrier 
lactose was observed. The salbutamol content in milligrams was 
obtained by the following equation: 
mg salbutamol sulphate =_AUC S/IS x Wst x dilution factor 
AUC St/IS 
where 
AUC S/IS is the area under the curve ratio of sample to internal 
standard 
AUC St/IS is the area under the curve ratio of standard to internal 
standard from calibration curve. 
Wst is the weight of standard in mg. 
2.3 Results 
2.3.1 Particle size analysis 
The mass medium diameter of micronized salbutamol sulphate was 
2.8pm with a geometric standard deviation of 1.3. The particle size 
distribution is shown in Figure 2.3. 
2.3.2 Moisture content 
The moisture content of salbutamol sulphate was found to be 0.8% 
w/w and was not higher than 0.05% w/w for the lactose samples. 
23.3 Content uniformity of the powder mixtures 
The mixing was found to be homogenous with a coefficient of 
variation of the sample contents ranging between 1.3-2.3% for the 
prepared mixtures. 
2.3.4 HPLC analysis of salbutamol sulphate 














Fig 2.3 Particle size distibution of micronized salbutamol sulphate 
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the internal standard versus salbutamol sulphate concentrations 
was obtained (Figure 2.4) with a correlation coefficient (r) of 0.998. 
A typical HPLC chromatogram is shown in Figure 2.5. 
2.4 Generation and sampling of a cloud 
In the design of the apparatus which permits in vitro evaluation of 
dry powder aerosols at various flow rates, it was desired to 
determine the size distribution and concentration directly using a 
commercially available cascade impactor. 
Since the flow rate of the sampler is fixed and the airflow proposed 
for cloud generation ranged between 60-200 I/min, two sampling 
methods were proposed to fulfil the basic requirement for 
isokinetic sampling. 
1 Method A: isokinetic sampling configuration that provides a 
gradual deceleration of the free stream velocity to match the 
suction velocity within a sampling probe of fixed diameter (Figure 
2.6a). 
2 Method B: isokinetic sampling employing probes the upper 
diameters of which were adjusted to achieve a suction velocity 
identical to the free stream velocity in a fixed diameter tube at 
different flow rates (Figure 2.6b). 
The sampling probes used in both configurations were fitted to a 
cascade impactor operated at an air flow of 28.31/min. 
2.4.1 The cascade impactor 
The cascade impactor (Anderson I CFM ambient) is shown in 
Figure 2.7. It consists of eight stages, 0 to 7, and a preseparator 
stage that are held together by three spring clamps and sealed with 
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O-ring. The preseparator stage is an impaction chamber with 
13.25mm inlet orifice and three outlet tubes. Each impactor stage 
contains multiple precision drilled orifices. The size of the orifices 
decreases with each succeeding stage, ranging from 2.55mm 
diameter in stage 0 to 0.25mm in stage 7. Each stage is fitted with a 
removable impaction plate for collection of the particles. The top 
two stainless steel collection plates have a 22mm opening in the 
centre to allow air flow through the centre. Each plate has a 
curved lip so that the air stream can flow around the edge of the 
plate to the next stage. The last stage is followed by a filter to 
capture all particles less than the cut off size of this stage. The 
impactor is connected to a vacuum pump which draws air through 
the instrument at a constant flow rate of 28.3 1/min. At this flow 
rate each impactor stage has a sharp cut off curve which gives the 
particle diameter having 50% collection efficiency (d50) (Figure 
2.8). The cut off size is reduced in each stage by decreasing the 
orifice size and increasing the velocity since the same mass of gas 
flows through each stage. As the sampled aerosol cloud flows in 
sequence through successive stages, the captured particles on a 
given stage represent a range of particle sizes smaller than the cut 
off size of the previous stage and larger than the cut off size of the 
given stage. The sequential separation classifies the aerosol cloud 
into fractions according to their aerodynamic diameters. 
The approximate cut off diameter for the various stages of the 
impactor, according to the manufacturers calibration, is shown in 
Table 2.1. 
To obtain an accurate aerosol size fractionation with the cascade 
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Fig 2.4 Calibration curve of salbutamol sulphate 
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Fig 2.7 Andersen 1 CFM ambient Schematic cross section of 











Fig 2.8 Ideal and actual impaction efficiency curve shapes 
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Table 2.1 The approximate cut off diameter for various stages of the cascade 
impactor 
Stage Cut off size (µm) 











adhere to it. However, dry solid particles were found to bounce 
from the surface upon impaction at a high air velocity (Turner and 
Hering, 1987). Distortion of the size distribution will occur if these 
particles are collected on subsequent stages (Nurtan et al, 1980). 
Therefore, to absorb the kinetic energy of the impacting particles 
and avoid re-entrainment, the preseparator stage and the impaction 
plates were coated with a thin film of 10% solution of silicon oil in 
hexane. The oil coating was stable and did not blow away as air 
was drawn through the impactor. This will preserve the shape of 
the distribution function. 
2.4.2 Apparatus A 
1. Design of Apparatus A 
The apparatus is depicted in Figure 2.9. In this apparatus a 
commercial powder inhaler device, the Rotahaler ( Allen and 
Hanbury's Ltd; Figure 2.10), containing an encapsulated dose of 
the powder mixture was assembled in a line conducting dried- 
filtered air at a rate up to 2001/min. The air supply was measured 
by a variable area flow meter with a flow range of 50-3001/min 
(Perflow Instruments, Ltd). On actuation of the device the powder 
was blown through a glass "throat" of 20mm internal diameter and 
having a right angled bend. The throat assembly was intended to 
simulate the oro-pharynx and is commonly included in models 
built by some investigators to represent the most realistic sampling 
conditions (Kirk, 1972, Hallworth et al, 1976,1986, Bell et al, 1973). 
The sample stream was then led from the throat to an expansion 
section which provided a gradual dec. eleration of the free stream 
velocity. This section consisted of a smooth conical glass diffuser 
with a divergent angle of 9°. The angle of the diffuser was 
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designed to be as small as possible to minimize flow disturbances 
caused by angles and bends. At different levels within the 
expansion section samples were drawn into the cascade impactor by 
means of sharp edged, thin walled, conical sampling tube of 150 
mm in length and 21.5 mm internal diameter. 
The thin walls and sharp edges reduce sampling errors caused by 
the finite dimensions of the tube which may disturb the flow field. 
The sampling tube, aligned parallel to the airflow direction, offers 
a sharp circular profile and reduces errors caused by non-isoaxial 
sampling. A minimum length of 150mm was required to facilitate 
sampling at different positions within the diffuser using the same 
tube. 
To achieve isokinetic conditions, the flow rate in the diffuser (Qo) 
and in the sampling tube (Q) were directly proportional to their 
respective cross-sectional areas. To calculate the position of the 
sampling tube within the diffuser at a particular air flow rate, the 




D is the sampling tube internal diameter and 
Do is the diffuser diameter at a particular flow rate. 
The position of the sampling tube within the diffuser at different 
flow rates is shown in Figure 2.9. The diffuser diameter and the air 
stream velocity at the sampling positions are given in Table 2.2. 
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Table 2.2 The diffuser and sampling tube characteristics at different flow rates in 
Apparatus A 
Qo Do QD, U= Uo 
1/min cm 1/min- cm cm/sec 
200 5.71 28.3 2.15 129.9 
150 5.00 28.3 2.15 129.9 
100 4.04 283 2.15 129.9 
60 3.10 28.3 2.15 129.9 
Qo: Flow rate within the diffuser 
Do: Diameter of the diffuser at the respective flow rate 
Q: Flow rate within the sampling tube 
D: Diameter of the sampling tube 













Fig 2.10 Powder inhaler device (Rotahaler, Allen & Hanbury's, Ltd) 
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2. Evaluation of Apparatus A 
Aspiration efficiency determinations 
The aspiration efficiency (+i) can be quantified by determining the 
ratio of the concentration in the samples (CN) to the concentration 




This ratio was employed as a means of judging whether a 
representative sample was removed from the aerosol cloud. A 
value of one, or close to one, indicates representative sampling. 
The aspiration efficiency was determined for powder mixtures with 
carrier sizes of 60-180/4m and <40um. Sampling was carried out in 
the following manner: 
The apparatus and the cascade impactor were inspected for a tight 
fit. The vacuum pump was set into operation and the dried- 
filtered air from the airline was adjusted to the specific flow rate. 
When steady flow was established, one end of the inhalation device 
was turned, the capsule was separated into two halves and the 
contents were dispensed into the air stream. Experiments were 
conducted at 60 and 150 1/min, each using ten capsules. This 
number of capsules allowed the collection of sufficient material for 
analysis on the various stages, but prevented re-entrainment of 
drug particles from the impactor collection surfaces as a result of 
the incoming particles impacting on collected particles rather than 
on the oiled surfaces. 
During sampling, only a portion of the generated cloud was 
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transported into the sampling tube. This portion varies according 
to the volume of air flowing through the sampling tube and in the 
annulus around it and is proportional to the respective cross- 
sectional areas. 
The portion of the cloud sampled at various flow rates is given in 
Table 2.3. 
Table 2.3 The percentage of aerosol cloud sampled at various flow 
rates 





Experiments were carried out by moving the sampling tube to 
equally spaced sampling points across the diffuser and at different 
points near the wall of the diffuser. The purpose of these 
experiments was to investigate the uniformity of the aerosol cloud 
within the diffuser since the generated cloud was polydispersed. 
After sampling was completed, the apparatus was dissembled 
and the amount of drug deposited in the inhaler and the capsules, 
the "throat", the preseparator stage, stages 0 to 2, stages 3 to 7 and 
the filter of the impactor, were separately rinsed with the internal 
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standard solution and the washings were assayed by the HPLC 
method described in Section 2.2.2. The stages were combined to 
collect sufficient material for the analysis. These combinations 
were made so that the cloud was fractionated into two size 
fractions: respirable, which was on stages 3 to 7, of size range 0.4- 
4.7pm and non-respirable, on stages 0 to 2 and the preseparator of 
size range 4.7-10µm and > 10µm, respectively. 
The total amount of salbutamol sulphate recovered from the 
combined stages was calculated and expressed as a percentage of 
the total dose released'. 
2.4.3 Results and discussion 
1. Aspiration efficiency 
The results of the aspiration efficiency determinations for the 
powder mixtures with carrier sizes of 60-180µm and <40µm, at 
different sampling points across the diffuser, are illustrated in 
Tables 2.4 to 2.7. 
The aspiration efficiency differed significantly at the different 
sampling points (P<0.01). A significant difference was also 
observed when sampling powder, mixtures with different size 
distributions and at different flow rates. 
The aspiration efficiency values were not close to unity in all cases 
(Tables 2.4 to 2.7). A value greater than one was obtained when 
sampling a cloud with 60-180&m carrier size at 150 1/min (Table 
2.4), whereas a value of less than one was obtained with the finer 
cloud of <40µm, carrier size, at the same flow rate (Table 2.5). At 
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a flow rate of 601/min, a value of <1 was observed with both 
carrier sizes (Tables 2.6 and 2.7). 
The variation in the collection efficiency between the coarse and 
fine carrier at 1501/min, might be explained by the deflection of 
the gas streamlines away from the centre of the diffuser, as a result 
of the right angled bend of the "throat". Allen (1975) noted that for 
the flow of solids in a 900 bend, concentrations are generally higher 
downstream along the duct wall farthest from the centre of 
curvature, and are lower along the duct wall nearest the centre of 
turning. Thus, coarse particles with high inertia persist in their 
original direction of motion; the amount entering the probe is less 
dependent on the sampling velocity. However, the fine particles, 
<40µm , 
follow more closely the deflected gas streamlines. 
Therefore, in this experiment, a reduced aspiration efficiency was 
observed as a result of the loss of some large particles from the 
moving air stream. At an airflow of 60 1/min, the sampling 
position, was moved upstream in the diffuser. At this sampling 
position the aspiration efficiency dropped significantly to less than 
one when a cloud comprising coarse carrier particles was sampled. 
A value still below one was also observed for the smaller size 
carrier; this value was significantly higher at 150 1/min. The 
possible reason for this is that at a sampling position 15mm 
downstream from the divergent angle of the diffuser, disturbances 
and eddy effects in the airflow are high, although the angle is small. 
To minimize these effects, Allen (1975) recommended that a site of 
eight to ten duct diameters downstream from a disturbance, caused 
by inlets, outlets, bends and constrictions, should be selected. 
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Therefore, the low aspiration efficiency indicates that some 
particles are blown away from the sampling tube as a result of these 
disturbances. However, the higher aspiration efficiency obtained 
with the finer carrier may be due to a fraction of the cloud being 
sampled upstream in the diffuser before complete deflection of the 
streamlines caused by the right angled bend. 
The data in Tables 2.4 to 2.7 reveal that fractions of a particular 
aerodynamic size distribution were significantly different as the 
sampling tube was moved to different sampling points across the 
diffuser. This was observed with the two carrier sizes and flow rates 
(P<0.01). 
This demonstrates that the aerosol cloud was unequally distributed 
over the cross-section of the diffuser. This non-uniformity is 
aggravated by the gas turbulence. The turbulence level can be 
estimated by Reynold's Number; estimated values at various 
sampling flow rates is given in Table 2.8. The values obtained were 
greater than 2000 indicating turbulent flow. However, these 
theoretical values do not adequately describe the effects caused by 
angles, bends and turbulent fluctuations across the cross-section of 
the diffuser and therefore underestimate disturbances. This is 
particularly true with a value close to 2000 indicating low levels of 
turbulence at a flow rate of 601/min. 
2. Throat deposition 
Since the "throat" was intended to simulate the oro-pharynx, it was 
of interest to investigate if it has a fractionating effect on the size 
distribution of the aerosol cloud. This has been assessed by 
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quantifying the amount retained by the preseparator stage which 
captures all particles larger than 10µm in diameter. The large 
fraction captured by this stage indicated that the "throat" was not 
efficient at removing large particles. The results in Tables 2.4 to 
2.7 show that at low air speeds the "throat" was collecting more 
particles, particularly, when the fine carrier was used. However, the 
collected fraction was markedly reduced at high air flow rates and 
when a coarse carrier was employed. These results were surprising 
since it was expected that at high air velocities and large particle 
size the impaction efficiency will be greater. This results from the 
large particles being unable to follow the diverging streamlines at a 
right angled bend due to their momentum causing impaction on the 
"throat" according to the theory described in Section 1.6 . This 
agrees with the findings of Hallworth and Andrews (1976). They 
observed that "throat" deposition occurs by impingement of the 
aerosol on the tubular inlet part of the "throat" due to gravitational 
effect and by inertial impaction of large particles on the right 
angled bend. Consequently, deposition falls with increasing air 
flow, as a rapid air flow sweeps the aerosol along the "throat" and 
minimizes contact with the "throat" wall. 
The "throat" in the present experiments was coated with a 10% 
solution of silicon oil in hexane to facilitate capturing of large 
particles. This, however, will not remain true following the 
actuation of the first few capsules since particles will cover the 
"throat" surface and subsequently the incoming particles impact on 
the collected particles rather than on the sticky surface. As a result, 
particle re-entrainment from the "throat" surface will occur and 
since the "throat" would not have a sharp cut-off ability, the physical 
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nature of the sampled cloud will vary affecting the principle of 
collecting a representative sample. 
3. Material losses 
On the sampling tube 
Losses between the inlet of the sampling tube and the impactor can 
not be avoided. These losses on the wall of the probe were 
quantified (Tables 2.4 to 2.7) and were found to be significant at all 
flow rates and with the two carrier sizes. Numerous mechanisms 
can operate to remove particles from the aerosol. These 
mechanisms include: impaction and sedimentation of large 
particles, diffusion of small particles to the walls and electrostatic 
interaction. Losses by these mechanisms increase with an increase 
in tube length (Fissan & Schioientek, 1987). 
In apparatus A, the length of 150mm was essential to facilitate 
sampling of the aerosol cloud at different levels within the diffuser 
using the same sampling tube. Particles deposited at the internal 
walls of the tube were removed from the cloud 'by one or more of 
the above mechanisms before they can actually be sampled. From 
the data in Tables 2.4 to 2.7 it was not possible to suggest whether 
the process was selective for a certain particle size. Therefore, 
these significant losses cannot be neglected as they reduce the 
overall sampling efficiency. 
On the diffuser 
Although losses on the walls of the diffuser did not exceed 10% 
(Tables 2.4 to 2.7), particles were observed to deposit mainly on its 
expansion angle. 
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Both turbulence and centrifugal effects may contribute to particle 
removal in bends(Fissan & Schioientek, £i987) dditionally, high inertia 
particles may also impact on the expansion angle of the diffuser as 
a result of a change in air flow direction. However, the data 
available provides no evidence as to whether cloud segregation 
occurred by selective removal of large particles from the cloud. 
Furthermore, wall losses were more pronounced with the finer 
aerosol cloud. These losses cannot be ignored as they may alter the 
nature of the sampled cloud and hence the collected sample may 
not be representative of the total aerosol cloud. 
Interstage losses 
Loss of particles on the preseparator lid, the jet inlets and the edges 
of the impactor stages are considered as interstage losses. 
Greasing the impaction plates was found to considerably reduce 
these losses. " 
This phenomenon was recognised by McFerland et al (1977) and 
Rao and Whitby (1978) who noted that all forms of the Anderson 
impactor have been shown to exhibit interstage losses especially in 
the few top stages. Interstage losses were found to result from high 
inertia of particles unable to turn sharply with the air streamlines at 
the jet inlets or around the plate edges as described in Figure 2.11. 
Owing to this mechanism, losses preferentially occur for larger 
particles and the general effect is a bias to small particle size. 
However, in the present study, since the quantified interstage losses 
did not exceed 1.0% of the total dose discharged and since this 




Fig 2.11 Diagram depicting wall loss due to overshootiof particles near 
jet entry 
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not considered serious and were not expected to bias the size 
distribution. 
From the above results, it can be concluded that although this 
apparatus was designed to give isokinetic sampling conditions, the 
aspiration efficiency values obtained were not acceptably close to 
unity, indicating that representative sampling was not achieved. 
It would appear that the overall performance of the apparatus was 
not only governed by matching the free stream velocity and the 
sampling velocity. Other factors appeared to have an effect on 
aerosol sampling and introduced errors into the system. 
Turbulence and eddy effects in the air flow pattern created by the 
right angled bend, made the behaviour of the aerosol flow 
downstream in the diffuser largely unknown. Furthermore, the 
transport of the cloud was markedly dominated by the particle 
properties, such as, inertia of large particles and ability of the 
small particles to respond to changes in air direction and turbulent 
fluctuation. Re-entrainment of particles from the "throat" surface 
and the substantial wall losses on the sampling tube, all affect the 
overall aspiration efficiency. 
Therefore, Apparatus A was considered unsuitable for sampling 
aerosol clouds generated at various flow rates. Elimination of the 
observed errors necessitated a total redesign of the apparatus. 
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Table 2.4 The percentage of drug deposited at various stages and the aspiration 
efficiency at different points across the diffuser at a flow rate of 150 I/min and a 
carrier size of 60-180µm. 
Stage -r/2 r+ r/2 
Device and capsules 15.5±0.9 16.0±1.8 17.0±0.8 
Throat 2.9±0.8 53±1.4 6.1± 1.1 
Diffuser 4.4±0.6 3.9±0.7 4.7±0.7 
Probe 3.4±0.9 4.6±1.1 4.7±1.8 
Preseparator 68.2±5.9 55.5±1.7 59.0±2.2 
Stages 0-2 0.3±0.2 3.3±0.9 4.8±0.8 
Stages 3-7 4.3±0.9 11.3±1.9 9.9±1.2 
Interstage losses 1.0±0.3 0.7±0.2 0.5±0.3 
Aspiration efficiency 1.4±0.10 1.3±0.09 1.2±0.08 
The results are the mean and standard deviation of six experiments. 
The aspiration efficiencies and the depositions at various stages of the 
impactor differ significantly at P<0.01 (t-test) 
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Table 2.5 The percentage of drug deposited at various stages and the aspiration 
efficiency at different points across the diffuser at a flow rate of 150 1/min and 
carrier size of <40im. 
Stage -r/2 r+ r/2 
Device and capsules 19.0±1.7 17.0±0.9 16.6±1.4 
Throat 10.3±0.9 8.6±1.7 9.8±1.9 
Diffuser 7.0±0.4 6.0±0.6 7.6±1.0 
Probe 5.0±1.9 4.9±1.3 4.6±1.9 
Preseparator 30.9±2.8 25.1±2.8 36.7±3.5 
Stages 0-2 5.9±1.2 10.9±1.8 8.7±1.1 
Stages 3-7 21.2±1.0 25.9±2.5 15.4±1.1 
Interstage losses 0.7±0.3 0.7±0.9 0.9±0.5 
Aspiration efficiency 0.6±0.08 0.7±0.32 0.43±0.01 
The results are the mean and standard deviation of six experiments 
The aspiration efficiencies and the depositions at various stages of the 
impactor differ significantly at P<0.01 (t-test) 
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Table 2.6 The percentage of drug deposited at various stages and the aspiration 
efficiency at different points across the diffuser at a flow rate of 60 I/min and 
carrier size of <40µm. 
Stage r r/2 
Device and capsules 25.0±0.8 23.4±0.6 
Throat 19.2±2.1 16.1±0.6 
Diffuser 10.5±1.1 12.6±0.8 
Probe 5.2±1.2 4.9±0.9 
Preseparator . 29.6±1.5 36.8±3.0 
Stages 0-2 4.7±0.5 3.2±0.3 
Stages 3-7 53±0.8 3.3±0.3 
Interstage losses 0.8±0.3 0.9±0.1 
Aspiration efficiency 0.8±0.04 0.9±0.06 
Sampling was carried out at two sampling points since the diffuser diameter 
was very small at this flow rate. 
The results are the mean an standard deviation of six experiments. 
The aspiration efficiencies and the depositions at various stages of the 
impactor differ significantly at P<0.01. 
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Table 2.7 The percentage of drug deposited at various stages and the aspiration 
efficiency at different points across the diffuser at a flow rate of 60 1/min and 
, carrier size of 60-180µm. 
Stage r r/2 
Device and capsules 143±03 14.9±0.5 
Throat 12.4±13 10.5±0.9 
Diffuser 5.8±0.2 6.1±0.7 
Probe 73±3.1 2.5± 1.4 
Preseparation 55±2.6 603±3.0 
Stages 0-2 2.6±1.2 0.7±0.4 
Stages 3-7 1.6±0.5 3.5±0.5 
Interstage losses 0.8±0.3 1.0±0.3 
Aspiration efficiency 0.7±0.06 0.8±0.06 
Sampling was carried out at two sampling points since the diffuser diameter 
was very small at this flow rate. 
The results are the mean and standard deviations of six experiments. 
The aspiration efficiencies and the depositions at various stages of the 
impactor differ significantly at P<0.01. 
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Table 2.8 Values of Reynold's Number at different flow rates In Apparatus A. 








2.4.4 Apparatus B 
Since isokinetic conditions were not achieved with apparatus A, 
apparatus B was constructed in the hope that some of the identified 
problems might be solved. 
1. Design of Apparatus B 
The apparatus is depicted in Figure 2.12. A powder inhaler device 
containing an encapsulated dose was assembled in a line 
conducting dried- filtered air at a flow rate up to 2001/min. On 
actuation, the powder was blown into a low angle, vertical glass 
diffuser 550mm in length with 20mm and 70mm inlet and outlet 
diameters, respectively. The "throat" was eliminated since the 
preseparator stage of the impactor captures all particles larger than 
10µm, simulating the mouth and oral cavity. The expansion angle 
of the diffuser was smoother than (7°) and the length was extended 
to five times the diameter. These modifications were intended to 
improve the airflow pattern and decrease the turbulence as the 
aerosol cloud travels down the length of the diffuser. At a 
minimum distance of four diffuser diameters from the expansion 
angle, samples of the aerosol cloud were continually drawn to a 
cascade impactor operated at 28.3 1/min, through sharp edged 
conical probes. 
The upper diameter of the probes was calculated so that the 
volume of air flowing through the probe and in the annulus around 
it, is proportional to the respective cross sectional areas. Equation 
2.1 was used to calculate the probe diameters at different flow 
rates. The length of these tubes was kept as short as possible to 
109, 
Fig 2.12 
Dried filtered air 
Inhalation device 







minimize wall losses. 
The characteristics of the sampling probes at different flow rates is 
given in Table 2.9. 
2. Evaluation of Apparatus B 
Aspiration efficiency determination 
This was determined at air flow rates of 60 and 150 1/min at 
different sampling positions within the diffuser as described 
previously in Section 2.4.2. 
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Table 2.9 The diffuser and sampling tube characteristics at different flow rates in 
Apparatus B. 
Qo Do QDU= Uo 
1/min cm 1/min cm , cm/sec 
200 7.00 28.3 2.63 86.6 
150 7.00 28.3 3.04 64.9 
100 7.00 28.3 3.72 43.3 
60 7.00 2.83 4.81 26.0 
Qo: Flow rate within the diffuser 
Do: Diameter of the diffuser 
Q: Flow rate within the sampling tube 
D: Diameter of the sampling tube at the respective flow rate 
U and Uo: Calculated sampling and air stream velocities respectively 
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2.4.5 Results and discussion 
1. Aspiration efficiency 
The aspiration efficiency obtained using this apparatus is given in 
Tables 2.11 to 2.15. No significant difference in the aspiration 
efficiency values was observed at air flow rates of 60 and 1501/min 
for powder mixtures of the same carrier size. However, a variation 
was observed when powder mixtures of different carrier sizes were 
used. The aspiration efficiency approached unity with the small 
carrier size (<40im), whereas a value between 0.75-0.80 was 
obtained with the coarse carrier (60-180µm). 
When the sampling tube was moved to different sampling points 
across the cross-section of the diffuser and near the walls as 
demonstrated in Figure 2.13, similar aspiration efficiency values 
were obtained for the fine and coarse carrier (Tables 2.10 to 2.14). 
These results demonstrate discrepancies in the overall sampling 
efficiency between the coarse and fine clouds. This is not 
surprising, since it has previously been observed that the turbulence 
of the airstream has little effect on the aspiration efficiency of small 
aerodynamic particle diameter, but its effect increased with particle 
size, especially for sizes above 4014m, due to inertia (Vincent et al, 
1985). Weiner et al (1988) found that turbulence has a pronouced 
effect on the overall sampling efficiency with the small inlet 
sampling tubes and the large particle diameter. 
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different flow rates (Table 2.15) was not appreciably lower than 
that for Apparatus A. However, in reality, the turbulence was 
substantially reduced in this apparatus, particularly at the sampling 
position as a result of sampling at a distance from a site likely to 
create air flow disturbances. 
Comparable aerodynamic size fractions were obtained from various 
stages of the impactor when sampling at different sampling points 
within the diffuser (Tables 2.10 to 2.14). This indicates the 
efficiency of mixing of the aerosol cloud and a uniform distribution 
of the coarse and fine particles across the diffuser. Vincent 
(1988) found that the free stream air turbulence tends to smooth 
out particle concentration gradients as a result of diffusive 
processes particularly for large particle sizes. 
The equal distribution of the cloud in Apparatus B may also be 
attributed to the fact that samples were drawn into the sampling 
tube at the same position from the bottom of the diffuser at all flow 
rates. This will have an advantage of minimizing errors caused by 
change in the air flow pattern as a result of the diffuser 
configuration. Additionally, this allows for cloud equilibration as it 
travels down the length of the diffuser before drawing the samples. 
2. Material losses 
On the sampling tube 
Wall losses were reduced to less than 1% in this apparatus as a 
result of the shorter length and the larger diameter of the sampling 
tubes. These losses were considered insignificant. 
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On the diffuser 
Losses on the walls of the diffuser varied with the particle size of 
the generated cloud. Higher losses were observed with the finer 
cloud which may be attributed to electrostatic effects. However, 
these losses were assumed to be non-selective for a certain particle 
size. This is because the fractions of small and large particles 
collected when sampling at different points across the diffuser and 
near the walls were similar, indicating no segregation of the aerosol 
cloud. Therefore, the core material within the diffuser was 
considered representative of the total aerosol cloud. 
Interstage losses 
Interstage losses within the cascade impactor were comparable to 
those observed previously and did not exceed 1%. 
Having completed the above experiments it may be argued that the 
low aspiration efficiency values obtained with the coarser cloud 
were due to the difference between the free stream velocity and the 
velocity within the sampling tube. Air velocities in the presence of 
suspended particles could be significantly different to those in the 
absence of particles, especially in turbulent flow (Nouri et al, 1987), 
whereas fluid and particle velocities are identical at low Reynold's 
Numbers (Yianneskis &-Whitelaw, 1984) 
Thus to ascertain that the free stream velocity and the velocity 
within the sampling tube were identical in the absence and 
presence of particles, a flow visualization experiment was essential 
to confirm the suitability of the system for isokinetic sampling. 
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Table 2.10 The percentage of drug deposited at various stages and the aspiration 
efficiency at different points across the diffuser at a flow rate of 150 1/min and a 
carrier size of 60.180µm. 
Stage -r/2 r+ r/2 
Device and capsules 14.3±0.4 15.1±0.2 14.9±03 
Diffuser 2.2±0.1 2.0±0.2 1.9±0.1 
Probe 0.9±0.1 03±0.0 0.8±0.0 
Preseparator 66.5±1.9 64.3±1.1 66.4±2.0 
Stages 0-2 1.5±0.1 1.6±0.1 1.4±0.1 
Stages 3-7 14.4±0.9 16.2±1.2 15.5±0.9 
Interstage losses 0.3±0.2 03±0.1 0.6±0.1 
Aspiration efficiency 0.8±0.01 0.8±0.03 0.8±0.02 
The results are the mean and standard deviation of six experiments. 
No significant difference in the aspiration efficiencies and the depositions at 
various stages of the impactor at P<0.05. 
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Table 2.11 The percentage of drug deposited at various stages and the aspiration 
efficiency at different sampling positions near the walls of the diffuser at a flow 
rate of 150 I/min and a carrier size of 60-180µm. 
Stage Position A Position B Position C Position D 
Device and Capsules 15.6± 0.9 16.2± 1.1 13.4± 1.3 14.2± 0.8 
Diffuser 2.1±0.1 " 1.9±0.1 2.3±0.1 2.610.1 
Probe 0.4±0.0 0.7±0.1 05±0.0 0.3±0.0 
Preseparator 63.3±2.1 61.7±2.0 66.6±2.5 65.0±1.8 
Stages 0-2 1.8±0.1 1.8±0.0 2.0±0.1 1.4±0.1 
Stages 3-7 16.1±0.7 17.5±0.9 14.8±0.4 14.9±0.7 
Interstage losses 0.7±0.1 0.3±0.1 05±0.1 1.0±0.0 
Aspiration efficiency 0.8±0.03 0.8±0.03 0.8±0.03 0.8±0.04 
The different sampling points are illustrated in Figure 2.13 
The results are the mean and standard deviation of five experiments. 
No significant difference in the aspiration efficiencies and the depositions at 
various stages of the impactor at P<0.05. 
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Table 2.12 The percentage of drug deposited at various stages and the aspiration 
efficiency at different sampling points across the diffuser at a flow rate of., 150 
1/min and a carrier size of <40µm. 
Stage -r/2 r +r/2 
Device and capsules 18.9±1.5 17.7±1.1 19.6 ± 0.9 
Diffuser 23.1±3.0 24.2±2.4 22.0±3.0 
Probe 1.0±0.1 0.9±0.0 0.9±0.0 
Preseparator 14.8± 1.2 14.2±0.9 15.5±1.1 
Stages 0-2 15.5±0.9 14.9± 1.4 16.1±1.4 
Stages 3-7 26.0±1.1 27.0±1.6 24.9± 1.9 
Interstage losses 0.8±0.1 1.1±0.1 1.0±0.02 
Aspiration efficiency 1.010.03 1.0±0.02 1.0±0.03 
The results are the mean and standard deviation of five experiments. 
No significant difference in the aspiration efficiencies and the depositions at 
various stages of the impactor at P<0.05. 
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Table 2.13 The percentage of drug deposited at various stages and the aspiration 
efficiency at different sampling positions near the walls of the diffuser at a flow 
rate of 150 I/min and a carrier size of <40, um. 
Stage Position A Position B Position C Position D 
Device and Capsules 17.9±2.3 17.5±2.9 20.4±1.8 18.9±2.0 
Diffuser 22.1±3.5 23.0±4.0 21.6±2.8 20.5±2.2 
Probe 1.0±0.1 0.8±0.03 0.6±0.03 1.0±0.1 
Preseparator 18.4± 1.8 20.0±0.9 18.9± 1.1 19.7± 1.3 
Stages 0-2 14.4±2.1 16.2± 1.0 13.3± 1.3 15.6± 1.0 
Stages 3-7 25.7±2.0 21.5±1.3 24.5±0.9 23.5±1.1 
Interstage losses 6.1±0.1 0.9±0.1 0.7±0.03 0.8±0.05 
Aspiration efficiency 1.1±0.02 1.0±0.05 0.9±0.08 1.1±0.05 
The different sampling points are illustrated in Figure 2.13 
The results are the mean and standard deviation of five experiments. 
No significant difference in the aspiration efficiencies and the depositions at 
various stages of the impactor at P<0.05. 
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Table 2.14 The percentage of drug deposited at various stages and the aspiration 
efficiency at a flow rate of 601/min with two carrier sizes. 
Stage Carrier size 
125-180µm <40µm 
Device and capsules 12.1±0.9 273±2.1 
Diffuser 2.1±0.1 6.1± 1.1 
Probe 0.0 0.6±0.0 
Preseparator 81.2±3.0 46.7±2.4 
Stages 0-2 0.5±0.0 8.9±1.4 
Stages 3-7 4.0±0.9 9.9±1.0 
Interstage losses 0.4±0.1 0S±0.0 
Aspiration efficiency 0.8±0.03 1.0±0.05 
The results are the mean and standard deviation of six experiments. 
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Table 2.15 Values of Reynold's Number at different flow rates in Apparatus B. 
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2.4.6 Flow visualization 
Several techniques have been employed for the measurement of 
the velocity of suspensions in gases, such as hot-wire anemometry 
and laser doppler anemometry. The latter offers an advantage over 
other techniques in that it is non-invasive and measurements can be 
made without disturbing the flow field. Therefore, this technique 
was employed to investigate the flow properties in Apparatus B. 
Air stream and particle mean velocities and turbulence intensity 
can be measured experimentally at fixed points using this method. 
The degree of turbulence, u/U, where, u, is the root mean square 
velocity and , U, is the mean flow velocity, obtained is almost 
independent of Reynold's Number. The latter describes the overall 
turbulence and is dependent upon the dimensions of the tube in 
which the air is flowing and the air velocity. However, the 
turbulence intensity measured by the laser technique, depends on 
the fluctuations in air velocities arising from eddies at certain 
points in the flow field. 
1. The laser anemometer optics 
The laser anemometer is shown schematically in Figure 2.14. The 
laser anemometer was operated with forward scattered light using 
a 10mW Helium-Neon laser and a rotating diffraction grating 
which splits the laser beam into two equal intensity beams that are 
focussed to a cross forming a control volume. A particle moving in 
this control volume causes a frequency shift of the light scattered by 
the particles. The scattered light is collected by a photomultiplier. 
The principal characteristics of the optical system are listed in 
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Table 2.16 The principal characteristics of the laser doppler 
anemometer 
Laser wavelength, nm 632.8 
Frequency-to-velocity conversion constant, m/s/MHZ 4.53 
Half-angle between incident beams, degrees 4.0 
Focal length of Lens F1, mm 200 
Focal length of Lens F2, mm 500 
Focal length of Lens F3, mm 200 
Beam spacing at Lens F3, mm 28 
Intersection volume diameter, um 95 
Intersection volume length, pm 1350 
Number of fringes in intersection volume 21 
Fringe spacing, µm 4.53 
Frequency shift, MHz 0.4 
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by the frequency counter. The measured frequencies are obtained 
from the digital output of the counter which is interfaced to a 
micro-computer, with which the mean and root mean square 
velocity components are calculated. 
The signal processing system and the output are shown in Figure 
2.15. 
2. Velocity and turbulence intensity measurements 
The modifications carried out on the apparatus to perform the 
necessary experiments are shown in Figure 2.16. The laser 
anemometer and ancilliary equipment were mounted on a 
platform, and the apparatus was fitted on a table to minimize 
vibrations transmitted to the platform. An adjustable table allowed 
the laser anemometry measurements to be taken at about 5 diffuser 
diameters from the bottom of the diffuser. Measurements across 
the diffuser were performed by moving the control volume . This 
was carried out by moving the optical unit (F3) along an optical 
bench, re-aligning the photomultiplier and adjusting the iris 
aperture with each increment (Figure 2.17). 
To evaluate the suitability of Apparatus B for isokinetic sampling, 
it was necessary first to confirm that the free stream velocity , Uo, 
and the velocity by the sampling tube, U, were identical both in the 
absence and presence of particles. These experiments were 
conducted without inserting the inhaler in the flow configuration. 
However, since the design of the inhaler might introduce some 
asymmetry to the flow field, experiments were performed with the 
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Fig 2.15 Signal processing system of the Laser-Doppler anemometer 
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Fig 2.16 Schematic diagram of the modified flow configuration 
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Enlarged view 
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Fig 2.17 Schematic representation of the experimental condition 
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But since the actual process was a transient release of particles 
rather than a steady flow, experiments were conducted to measure 
the particle velocity after breaking the capsule to verify that this 
does not account to any significant alteration in the sampling 
process. 
These experiments were conducted in the following sequence: 
First the mean and root mean square velocities (indicating the 
turbulence intensity) of the steady airflow through the diffuser, 
without the inhaler, were measured at 60,100,150 and 2001/min, 
using silicon oil droplets of <2µm mean diameter as seeding 
particles. These droplets, generated by an atomizer, are small 
enough to follow closely the gas streamlines and thus, the velocity 
recorded is the velocity of the gas carrying these particles 
(Yianneskis 1987). Measurements of the steady airflow velocity 
were made across the diffuser at three axial locations: 110mm 
upstream from the probe, 10mm upstream from the probe inlet and 
10mm downstream from the probe inlet, both inside and in the 
annulus around it. The sampling tubes were made from perspex to 
enable optical access. 
For the second set of measurements, particle and r. m. s. velocity 
measurements at flow rates of 150 and 2001/min were made using 
clouds of lactose particles of size fractions <40µm and 60-180µm. 
A section of the small pipe (at location A in Figure 2.16) 
incorporated a convergent nozzle to induce local flow acceleration 
and a reduction in pressure. At the point of minimum pressure, a 
small funnel was attached to the pipe wall through which solid 
particles could be introduced. The flow through the funnel was 
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measured during each test with a hot-wire anemometer. Particles 
were gravity fed into the diffuser using a vibrating spatula which 
has been previously adjusted to introduce particles at 
approximately 1.6 g/min. 
In the third set of experiments, the inhaler was inserted in the 
diffuser at location B (see Figure 2.16). Measurements were made 
at 1501/min for the steady air flow and the solid particle flow, as 
described above. 
In the fourth experiment, the rotating section of the inhaler was 
coupled to a stepper motor as shown in Figure 2.16. A capsule was 
loaded with 140mg of powder to maximize the resolution as the 
particles crossed the control volume. The motor rotated the upper 
half of the inhalation device to break the capsule and this operation 
was synchronized with the measurement of particle velocities 
released at 60 1/min. The rotation of the stepper motor 
simultaneously triggered the frequency counter measurements. 
The analogue output of the counter was interfaced to a second 
micro-computer which was used to calculate the velocity at each 
recording. 
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2.4.7 Results and discussion 
Representative measurements for air stream and r. m. s. velocity 
components at a flow rate of 1501/min are shown in Figure 2.18. 
The results obtained at the other flow rates are given in the 
Appendix . The results 
indicate that air stream and sampling 
velocities were similar upstream in the diffuser, upstream before 
the sampling tube, in and around the sampling tube. The velocity 
profiles were flat across the diffuser and they were not significantly 
disturbed by the presence of the probe. The results also indicate 
that the turbulence intensity was high within the diffuser; however, 
turbulent fluctuations were uniform across the cross-section. 
Similar results were obtained at all flow rates. 
Particle velocities at a flow rate of 1501/min, from each of the two 
size fractions 60-180µm and <40µm, are compared with the gas 
velocities in Figure 2.19. All the measurements made indicated 
that the particle mean and r. m. s. velocity profiles were similar, 
upstream before the sampling tube, inside, and in the annulus 
around it. However, the mean velocities of the large particles are 
about 0.16m/sec higher than those of the smaller ones, which in 
turn are about 0.04m/sec larger than those of the air flow. This can 
be expected as gravity acts in the down flow situation so as to 
increase the particle velocity. The r. m. s. velocity results shown in 
Figure 2.19 indicate that there is an increase in turbulence as 
particle size increases, as well as in comparison to gas flow. The 
latter results are in agreement with the findings of Lee (1985), who 
observed that the particle r. m. s. velocity was higher than the 
131 
,ýý, 
single-phase gas r. m. s. over most of the pipe cross-section for most 
Reynold's Numbers examined. 
Measurements obtained with the inhaler device inserted in the 
airline at a flow rate of 1501/min are shown in figure 2.20. The air 
and particle mean velocities were similar to those shown in Figure 
2.19 in the absence of the inhalation device. The profiles were 
uniform, indicating that the flow recovers soon after its passage 
through the inhaler and that the asymmetry in its design has no 
influence on the air flow pattern down stream from the diffuser. 
Therefore from these measurements, it was verified that the 
velocity of the air stream and the particles of the two size fractions 
were similar at the sampling point. Hence, neither the geometry of 
the diffuser nor the presence of the inhaler could account for the 
reduced aspiration efficiency observed for the coarse carrier 
particles. 
The velocity trace obtained by the transient particle release at an 
air flow of 60 1/min is shown in Figure 2.21. For a short period 
after breaking the capsule, there were no particles crossing the 
control volume which was located 10mm above the sampling tube 
and approximately 500mm downstream of the device. For this 
reason the velocity record was initiated with a small delay after 
breaking the capsule. The average velocity value indicated in the 
trace after the first 0.5 seconds was in agreement with the steady air 
flow velocity at 601/min. This was 0.35m/sec. Therefore, it is 
suggested that the velocity profiles are not noticeably affected by 
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Gas and particle flow at 150 I/min upstream before the probe In the presence of the Inhaler 
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Fig 2.20 Profiles of axial mean (open symbols) and r. m. s. (solid 
symbols) velocities at an airflow of 150 I/min 
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Having established that the transient nature of the process did not 
account for any significant alteration in the sampling process and 
confirmed that the free stream and the sampling velocities were 
identical under all experimental conditions, it can be concluded 
that isokinetic sampling conditions have been achieved. 
However, these measurements did not explain the reason for the 
difference in the aspiration efficiency observed for the coarse and 
fine aerosol clouds. A possible explanation is that particles of unit 
density and of a radius s 30µm are completely entrained by the 
conveying gas and are expected to follow the turbulent fluctuations, 
whereas coarser particles of radius equal to 100µm are found to be 
only 70% entrained by turbulent fluctuations (Fuchs, 1964). Owing 
to inertial and gravitational effects large particles move faster than 
the conveying air stream, thus the level of entrainment is reduced 
increasing the particle size. 
Another possible reason might be related to the dimensions of the 
sampling tubes. In reality, the thin walled sampling tube does not 
exist, since the tube walls must have a finite thickness and so 
present some blockage to the air movement no matter how small. 
Vincent et al (1982) noted that at the sample orifice the flow may 
be considered to consist of two parts, the outer one dominated by 
the flow about the sampler body, and the inner one dominated by 
the flow into the sampling orifice. This type of flow tends to disturb 
the gas streamlines at the sampling tube entrance and will depend 
on the wall thickness. Therefore, particles approaching the 
entrance of the tube might be subjected to some changes in the 
direction of air motion. These could cause them to experience 
inertial forces and so undergo deflection even if the changes were 
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minor. It would be expected that this effect will be more 
pronounced for the larger particles. However, having established 
that the fractionation of the sampled cloud into different 
aerodynamic size fractions was similar at different sampling points 
within the diffuser, it is possible to suggest that the sampling 
process was representative for both size fractions and the devised 
apparatus is suitable for isokinetic sampling. 
By means of isokinetic sampling, Apparatus B permits the 
evaluation of formulation variables in powder inhalation aerosols 
in terms of inspiratory effort. This has not been possible in earlier 
studies which sampled the total aerosol cloud with conventional 
impactors usually calibrated at flow rates not exceeding 601/min. 
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Chapter three 
The effect of airflow, inhalation device and formulation 
variables on the characteristics of a cloud 
Introduction 
Mixing fine drug particles with a coarse carrier is the most common 
way of formulating dry powders for inhalations. The mixture 
formed can be described as an ordered mixture (Hersey, 1975). 
In dry powder aerosols, redispersion of the drug particles from 
their agglomerates or from the surface of the carrier as single 
entities during inhalation, is the most critical factor which governs 
the availability of the medicament to the lungs. This will depend 
on the mechanical stability of the powder mixture, the way this is 
influenced by the adhesion characteristics between the drug and 
the carrier, and the external forces required to break up the bonds 
formed between adhering particles. 
In ordered mixtures, the adhesion characteristics between the drug 
and the carrier can be influenced by several factors. These include: 
the surface properties of the carrier, the particle size of the two 
components, the presence of other components, the relative 
humidity and electrostatic behaviour. These factors influence the 
entrapment of fine drug particles within the clefts and pores on the 
carrier surface and interfere with the strength of the interparticle 
forces. 
High relative humidities result in an increase in the adhesive forces 
due to capillary action. However, the electrostatic forces, which 
predominate at low humidities, may increase or decrease the 
mechanical stability of powder mixtures since powders have 
different dielectric constants. In powder aerosols, electrical 
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charges may arise during mixing or may be induced on the powder 
particles during inhalation as a result of powder bed fluidisation. 
Literature reports concerned with the basic principles governing 
the generation of medical powder aerosols are sparse. The concept 
of the influence of air flow through the device on its performance 
as an insufflator was introduced by Bell et al, (1971) who also 
reported the size of the carrier which provides optimum flow 
properties of the powder. Other workers (Chowhan and Amero, 
1977) attempted to introduce possible formulation variables which 
might improve the performance of dry powder aerosols. They 
investigated the importance of selecting a proper drug entity in 
designing powder aerosols. The delivery efficiency of an organic 
acid and a salt from powder blends, under ambient conditions and 
following equilibration of the powders under various humidity 
conditions were compared. Further in vitro studies were carried 
out by Chowhan and Linn (1978) to investigate the effect of the 
drug dose and the drug to carrier ratio on the delivery efficiency of 
these drugs. Vidgren et al (19874 studied the effect of fine drug 
particles, produced by two different size reduction methods, on the 
deposition behaviour of mixtures containing equal proportions of 
the drug and the carrier. 
However, none of the above investigations provided a basic 
understanding of the powder properties and their behaviour in 
turbulent air stream. Evaluations were performed at low and fixed 
flow rates, whereas in reality the cloud might be generated at flow 
rates which vary according to the patient's disease state and 
normally higher than those employed. The behaviour of the 
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aerosol cloud might well differ at different and higher air speeds. 
Moreover, varying the carrier size and its proportion in the 
formulation was mainly carried out to improve the flow properties 
of the powder mixtures at the low flow rates employed. No attempt 
has been made to relate the behaviour of powder aerosols to the 
nature of the adhesive forces and the external accelerative forces 
required to act at the drug-carrier interface to overcome the 
interparticulate forces. 
Therefore in the following study, fundamental knowledge on 
adhesion was applied to powder aerosols. Formulation variables 
were varied according to the factors which were expected to affect 
the adhesion characteristics and for which the force required to 
redisperse the fine drug particles was altered by changing the flow 
rate and the turbulence within the inhalation device. 
3.2 Materials and methods 
3.2.1 Characterization of powders 
1. Classification of carriers 
Lactose monohydrate (regular) was classified into different size 
fractions as described in Section 2.2.1. Milled glass and spray dried 
lactose (Pharmatose, De Melkindustrie Vegh) were classified by an 
"Alpine" air jet sieve to obtain a size fraction between 63-901im. 
The glass beads were 60µm in size and recrystallized lactose was 
obtained in the size range of 60-90µm by crystallizing lactose 
monohydrate under controlled conditions. 
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2. Particle size analysis 
The particle size distribution of the micronized salbutamol sulphate 
was determined by the method described in Section 2.2.1. 
The size distribution of the recrystallized lactose was determined 
by image analysis optical microscopy. Slides were prepared by 
dispersing a very small amount of the powder. Fields were selected 
randomly and the image was projected onto a computer screen. 
The perimeter of each particle in the field was traced using a 
graphic tablet; 500 particles were measured to obtain a statistically 
significant value. The size distribution ranged between 60-90µm. 
3. Flow properties of powders 
The flow of the carriers was measured by discharge through an 
orifice. A tube fitted with a circular orifice 5.8mm in diameter was 
filled with 200g powder and the flow rate was measured by 
weighing the amount of powder escaping from the orifice in 15 
seconds after steady state condition was established. Lactose 
fractions of <20µm and < 10µm were too cohesive for this 
experiment and a tensile strength test was performed. 
Results are shown in Table 3.1. 
4. Tensile strength measurement -. 
The tensile strength of micronized salbutamol sulphate and lactose 
in the size fractions of <20µm and <10µm was measured over a 
range of packing fractions from 0.1 to 0.6 using a split plate tensile 
tester (Ajax Ltd). 
Figure 3.1 shows the log tensile strength (Nm 2) against packing 
fraction for the three powder samples tested. The results were 
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found to fit the general equation: 
Log T= A1Pf + A2 (3.1) 
where: T is the tensile strength, Pf is the packing fraction and Al 
and A2 are constants for each sample. 
The tensile strength, at any particular packing fraction, decreased 
in the order: 
micronized salbutamol sulphate > lactose (< 10µm) > lactose 
(<20µm) 
S. Moisture content 
The moisture content was determined for all the powders using an 
infra-red moisture balance and did not exceed 1.0% w/w. The 
powders were stored in sealed jars over silica gel. 
6. Carrier surface characterization 
-1 
a. Scanning electron microscopy 
Scanning electron microscopy was used to examine the surface 
texture of the carriers. Photomicrographs of particle surface details 
are produced in Figure 3.4. 
b. Surface roughness (rugosity) determination 
The surface roughness (Rs) was determined by comparing the 
external specific surface area obtained by an air permeation 
method (So) withýthe theoretical surface area when the particles 
are considered as spheres (Sd) measured from projected particle 
diameter: 























Fig 3.1 The relation of Log tensile strength to packing fraction for 
three powder samples 
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Table 3.1 The flow properties of the carriers 
Carrier Flow rate( g/min) 
Glass beads (601im) 419.4 
Milled glass (63-90µm) 291.0 
Spray dried lactose (63-90µm) 120.0 
Regular lactose (63-90µm) 125.2 
Regular lactose (125-180pm) 183.0 
Regular lactose (20-40µm) 25.7 
Recrystallized lactose (60-90Nm) 118.0 
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The determination of the specific surface area by the air 
permeation method employed a Fisher sub-sieve sizer which 
measures the ability of air to flow through a packed bed of powder. 
For a given pressure, flow will depend on the average pore 
diameter and the total interstitial surface, both characteristics 
being influenced by the rugosity of the material. 
A mass of powder equal to its true density(P) is compressed to a 
known porosity in the cell of the Fisher sub-sieve sizer. The flow 
rate through the bed at a fixed pressure differential is transcribed 
by the instrument to an average particle diameter (dm). This 
diameter is derived from the specific surface area of the powder 




For the calculation of theoretical surface area from microscopic 
data, the following equations were used: 
S= 7rds2 (3.4) 
V=ird) (3.5) 
6 
where ds is the diameter of a sphere having the same surface (S) as 
the particle and dv is the diameter of a sphere having the same 
volume (V) as the particle. 
These two equations can be applied to obtain the surface area (Sd) 
by the relation: 
Sd = S/V x Pp (3.6) 
where Pp is the true density of the powder. 
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3.2.2 Preparation of capsules 
Blends of salbutamol sulphate and the carriers were prepared and 
examined by scanning electron microscopy. The mixtures were 
filled into hard gelatin capsules by the method described in Section 
2.2.1. 
3.2.3 Evaluation of powder aerosols 
Apparatus B, described and evaluated in Chapter 2, was used for 
the assessment of the dry powder aerosols at various flow rates. 
The "Rotahaler" was employed for cloud generation unless 
otherwise specified. 
3.2.4 Determination of salbutamol sulphate deposited at various 
stages 
The fractional deposition pattern of salbutamol sulphate was 
determined by HPLC analysis as described in Section 2.2.2. 
3.3 The effect of the external forces on the characteristics of an 
inspirable aerosol cloud 
During inhalation of a powder mixture, the separation force is 
provided by two components: the inspiratory flow rate and the 
turbulence created within the inhaler as air flows through it. 
These two components are inter-related, i. e, the higher the flow 
rate, the greater is the turbulence within the inhaler. However, 
turbulence can also be increased by varying the construction of the 
inhaler. 
In the following study these two components were investigated as 
follows: 
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3.3.1 Materials and methods 
1. The effect of air flow rate 
To study the influence of the flow rate on the inspirable 
characteristics of the aerosol cloud, flow rates of 60,100,150 and 
2001/min were employed. 
An air flow of 601/min was the lowest used as this is probably the 
minimum inspirational flow for an asthmatic patient through a 
"Rotahaler". Furthermore, lower flow rates may not produce 
adequate fluidisation of the powder bed within the inhaler. An air 
flow of 2001/min was the maximum used since clinical studies have 
shown that this flow rate is attainable by mild asthmatics. 
2. The powder mixture 
Blends of micronized salbutamol sulphate (2.81im MMD) and 
unclassified lactose prepared in a ratio of 1: 67.5 were investigated. 
Results and discussion 
In the following discussion the deposition pattern of salbutamol 
sulphate fractionated as described in Section 2.4.2 will be 
interpreted as follows: 
The preseparator stage simulates the mouth and the oral cavity. 
Drug particles captured in this location are present either as drug 
agglomerates of aerodynamic diameter > 10µm or as a drug 
adhering on the surface of the coarse carrier. - 
Stages 0 to 2 simulate capture by the upper respiratory tract. The 
drug recovered from these stages is either; as agglomerates of 5. 




Stages 3 to 7 simulate the lower part of the respiratory tract. Drug 
particles deposited on these stages are in the size range of 0.4- 
4.7pm and are described as respirable. 
The effect of air flow rate on the inspirable characteristics of a 
cloud 
The results of the effect of air flow rate on the drug deposition is 
shown in Figure 3.2. An increase in the flow rate resulted in an 
increase in the fraction deposited on stages 3 to 7. For instance at 
an air flow of 60 1/min, 13.2% of the drug was respirable, in 
comparison with 27.7% at an air flow of 2001/min. On the other 
hand, the amount of drug recovered from the preseparator stage 
(Table 3.2) indicates that dissociation of the drug from the carrier 
surface is greater at high air speeds. 
Similar results were observed by Kim et al (1985) who investigated 
the influence of air flow rate on the size distribution of sodium 
cromoglycate powder aerosol generated from a "Spinhaler". 
Despite the inaccuracy of the sampling technique they adopted, 
where samples of the aerosol cloud were anisokinetically collected 
by a cascade impactor, their results indicated that a finer cloud was 
generated at a flow rate of 80 1/min than at a 50 1/min. The 
importance of air flow rate lies in the ability of the air stream to 
create a high level of turbulence within the inhaler, thus breaking 
up the aggregates and agglomerates into singly dispersed particles 
that can penetrate deep into the lungs. Additionally, if the force 
provided by the drag and lift of the air stream on the adherent 
particles exceeds the force of adhesion, particle detachment from 
the carrier surface will occur. 
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Table 3.2 The percentage of drug deposited at various stages at different flow rates 
using unclassified lactose as carrier 
Flow rate 
(1/min) 
Device Preseparator Stages 0-2 Stages 3-7 
200 19.2 22.3 8.4 27.7 
150 19.9 22.4 8.5 26.7 
100 19.9 26.4 11.9 21.5 
























Fig 3.2 Effect of airflow rate on the amount of drug deposited on stages 3-7 
using unclassified lactose 
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50 100 150 200 
FlowrateO/min) 
The drag force directed on adherent particles will be determined by 
the particle size and air velocity employed according to the 
relation: (Corn & Stein, 1965) 
F(drag) = CPV2Dp2/2 
where 
(3.7) 
C is the drag coefficient of particle 
P is the air density 
V is the air velocity 
and DP is the particle diameter 
From this relation, it is obvious that high air velocities are needed 
to detach small adherent particles. 
The effect of the air flow rate on the pattern of drug deposition will 
be illustrated throughout this chapter as all the formulation 
variables were evaluated at different flow rates. However, most of 
the subsequent experiments were conducted at 60 and 1501/min 
since these two speeds represent a low and somewhat high 
inspirational efforts. 
3.3.2 The effect of turbulence 
The turbulence level can be increased within the inhaler without 
varying the air flow rate. In the following study the influence of 
turbulence was investigated when an aerosol cloud was generated 
at 601/min. I 
To vary the turbulence as air flows through the inhaler at a constant 
speed, an inhalation device was designed in a way which facilitates 
the introduction of nozzles of different diameters and the insertion 
of grids at different positions. The inhaler is depicted in Figure 3.3. 
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It consists of a tube with an internal nozzle. A capsule containing a 
unit dose can be inserted at the end of the inhaler. 
The powder mixture 
FAends of salbutamol sulphate (2.8µm MMD) and lactose(63-90zm) 
prepared in a ratio of 1: 67.5 were investigated. 
1. Chang: in nozzle diameter 
Using the above inhaler to generate the aerosol cloud, it was 
possible to change the nozzle diameter thus varying the turbulence. 
Experiments were conducted using nozzles of 20,15,12,10 and 
5mm internal diameter. Dispensing of the powder aerosol was 
performed by sealing the capsule after filling and inserting a thin 
needle vertically within it. As the end of the inhaler containing the 
capsule was turned, the needle passing through the body of the 
capsule was pushed against a shaft within the inhaler causing the 
bottom of the capsale to break. This procedure was essential to 
prevent the carsule lialf containing the powder from being carried 
by the air stream or blocking the narrow nozzles. The level of 
turbulence within the nozzles was estimated by Reynold's Number. 
2. Grid inserts 
The use of grids or screens is the most common means of inducing 
turbulence in wind tunnels (Wienner et al, 1988). In the following 
study, grids of 1.0mm and 0.5mm mesh spacing were inserted into 
the inhaler at position A, B or A and B as shown in Figure 3.3b. 




Fig 3.3 a. Designed inhaler 
GridA 
Grid B 
Fig 3.3 b. Inhaler with grids inserted 
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When a grid was inserted at position A or A and B, dispensing was 
performed by turning one end of the inhaler which contains the 
encapsulated dose, separating the capsule into two halves. The 
part containing the powder dropped into a chamber where it was 
retained by the grid and the powder was dispensed into the air 
stream through the nozzle. However, when a grid was inserted at 
position B, dispensing of the powder was performed as described in 
the above section to hinder blocking of the narrow nozzles. As air 
flows through the inhaler, the powder was dispensed to the nozzle 
and passed through the grid into the air stream. 
3. The resistance to air flow 
The pressure drop created by the inhaler at all the above 
configurations was measured using a mercury manometer to 
determine the resistance of the inhaler to airflow. 
Results and discussion 
The effect of the different levels of turbulence generated by 
changing the nozzle diameter on the pattern of drug deposition at 
various stages is shown in Table 3.3. The pressure drop created by 
the inhaler at these configurations is also given. 
An increase in turbulence resulted in a relatively small increase in 
the respirable fraction as the nozzle diameter was reduced from 20 
to 10mm. When a nozzle of 20mm was used, 1.9% of the drug 
deposited on stages 3 to 7 compared to 4.9% with a nozzle 
diameter of 10mm. However, when the nozzle diameter was further 
reduced to 5mm, 11.3% of the drug was recovered from stages 3 to 
7. The amount of drug deposited in the preseparator stage was 
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inversely related to Reynold's Number. As for the amount of drug 
retained in the inhaler, a slightly higher amount was recovered with 
the smaller nozzle diameters. Moreover, the reduction in the 
nozzle diameter was accompanied by a noticeable rise in the 
pressure drop created by the inhaler as air flows through it. The 
pressure drop increased from 0.09 kPa to 1.53 kPa when the nozzle 
diameter was reduced from 20mm to 5mm, respectively. 
Turbulence is directly related to air velocity. In the above 
experiment the higher air velocities were achieved by decreasing 
the cross-sectional area of the air channels as air flows at a constant 
rate of 601/min. Therefore, the degree of turbulence is dependent 
upon the internal dimensions of the inhaler. 
The above results indicated that the increase in turbulence 
provided more effective de-aggregation of the powder mixture. 
This agrees with the findings of Vidgren et al (1987) who 
demonstrated that the narrower the air channels within inhalation 
devices, the more efficient is the drug deposition in the respiratory 
tract. Therefore, a further reduction in the internal dimensions of 
the inhaler might additionally improve the efficiency of a dry 
powder aerosol. However, this will lead to an increase in the 
resistance of the inhaler to air flow and thus to a difficulty to inhale 
through it at a flow rate which produces optimum drug delivery. 
This problem is of great importance particularly with some patients 
such as children and severe asthmatics. Therefore, there is a need 
to design an inhaler which provides high levels of turbulence 
without further increase in the resistance to air flow. This can be 
achieved by introducing grids of varying mesh size by the way 
described in Section 3.3.2. 
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Table 3.3 The effect of different levels of turbulence generated by changing the 
nozzle diameter on the pattern of drug deposition at various stages 
% Drug deposition at various stages 
Nozzle Reynold's Pressure Device Preseparator Stages Stages 
diameter Number drop 0-2 3-7 
(mm) (kPa) 
20 4240 0.093 12.3 85.1 1.0 1.9 
15 5660 0.113 8.1 85.8. 2.1 3.9 
12 7080 0.120 10.3 80.8 0.7 5.1 
10 8500 0.147 17.5 78.1 0.6 4.9 
5 17000 1.53 15.7 71.9 11.3 
; ýy 
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The results of introducing grids are illustrated in Tables 3.4 and 3.5. 
Inserting grids of 0.5mm and 1.0mm mesh spacing at positions A, B 
or A and B resulted generally in an increase in the respirable 
fraction. However, the increase depended on the position of the 
grids and the size of the mesh. When an inhaler of a 10mm nozzle 
diameter with the grid inserted at position A was used, a slight 
increase in the respirable fraction was observed with both the 0.5 
and 1.0mm mesh spacing grids (Table 3.4). However, a greater 
increase in the amount of drug deposited on stages 3 to 7 was 
noticed when a grid of 0.5mm mesh spacing was inserted at position 
B. Without a grid, 4.9% of the drug was recovered from stages 3 to 
7 in comparison with 11.3% when a grid was inserted at position B. 
Insertion of grids at positions A and B produced similar results as 
when the grid was inserted at position B. 
When an inhaler of 5.0mm nozzle diameter was used, comparable 
results as those observed with the 10mm nozzle inhaler were 
obtained. However, a higher amount of the drug was recovered 
from stages 3 to 7 (Table 3.5). The major increase in the respirable 
fraction was observed with the grid inserted at position B; 30% and 
50% of the drug deposited on stages 3 to 7 with the 1.0mm and 
0.5mm mesh spacing grids, respectively in comparison with 11.3% 
without a grid and 15% with a grid inserted at position A. 
Similar results were obtained when two grids were inserted in the 
inhaler indicating that the grid at position A had no appreciable 
effect on the respirable fraction. Additionally, the use of two grids 
in the inhaler did not contribute to a further increase in the 
respirable fraction. 
The increase in the respirable dose was always associated with a 
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decrease in the amount of drug recovered from the preseparator 
stage, indicating a greater dissociation of the drug from the carrier 
surface. - The data in Table 3.5 also indicate that more drug was 
retained in the inhaler as a result of inserting the grids, particularly 
at position B or A and B. When an inhaler without a grid was used, 
15.7% of the drug was recovered from the inhaler in comparison 
with 34%, when grids were inserted at these positions. 
Therefore, the results suggest that the level of turbulence has 
increased within the inhaler and was dependent upon the position 
of the grids and the mesh spacing. Higher turbulence was created 
with the grid inserted after the nozzle (position B), particularly with 
the 0.5mm mesh spacing; a respirable fraction of up to 50% was 
obtained. In contrast, the grid at position A induced only a slight 
increase in turbulence. 
The turbulence produced by the grids was generated through the 
work done by the airltream against the drag imposed by the grid 
elements. This type of turbulence is known to be homogenous 
(Wiener et a1,1988). However, although the bar width was smaller 
with the 0.5mm mesh spacing grid, the turbulence generated was 
higher. This might be attributed to the larger number of elements 
composing the grid. 
Therefore, the high retention of the drug in the inhalation device 
observed can be explained in terms of increased contact between 
the powder mixture and the walls of the inhaler due to turbulence 
and eddy effects and also the availability of additional surfaces. 
From these results it can be concluded that the turbulence created 
by the inhalation device is of great importance in generating highly 
inspirable clouds. Turbulence results in a reduction in the laminar 
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Table 3.4 Effect of Inserting grids of various mesh spacing at different positions 
within the inhaler of 10mm nozzle diameter on the percentage drug deposition at 
various stages 
Grid at position A 
Grid mesh Pressure drop Device Preseparator Stages 0-2 Stages 3-7 
spacing 
(mm) (kPa) 
1.0 0.147 20.4 76.1 0.5 5.9 
0.5 0.147 22.8 70.4 0.7 6.1 
Grid at position B 
Grid mesh Pressure drop Device Preseparator Stages 0-2 Stages 3-7 
spacing 
(mm) (kPa) 
1.0 0.147 23.4 69.0 0.9 6.8 
0.5 0.147 183 70.0 0.0 11.3 
Grid at position A and B 





0.147 24.2 69.0 0.0 8.4 
0.5 0.147 23.0 63.4 1.3 13.0 
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Table 3.5 Effect of inserting grids of various mesh spacing at different positions 
within the inhaler of 5mm nozzle diameter on the percentage drug deposition at 
various stages 
grid at position A 
Grid mesh Pressure drop Device Preseparator Stages 0-2 Stages 3-7 
spacing 
(mm) (kPa) 
1.0 1.53 22.1 66.0 1.3 10.5 
0.5 - 1.53 23.9 61.1 
0.0 15.0 
Grid at position B 















Grid at position A and B 
Grid mesh Pressure drop Device Preseparator Stages 0-2 Stages 3-7 
spacing 
(mm) ('RPa) 
1.0 1.53 35.0 39.1 0.4 27.6 
0.5 1.53 31.3 23.0 0.0 49.9 
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sublayer at the drug-carrier interface to overcome the 
interparticulate adhesion forces, resulting in the adherent particles 
becoming detached. 
However, the most interesting observation is that the insertion of 
grids within the inhaler at different positions, and with varying 
mesh spacing, did not contribute to a further increase in the 
pressure drop. This indicates that turbulence can be maximized 
without an increase in the resistance of the inhaler to air flow. 
Therefore, on the basis of this study an inhaler was designed to 
generate a deeply inspirable aerosol cloud with a minimum effort 
on the part of the user. 
3.4 The effect of the adhesion properties of a powder mixture on 
the characteristics of an inspirable aerosol cloud 
Since the drug and the carrier are normally the only constituents of 
dry powder aerosols, the formulation might be improved by 
modifying the relationship between these two components. The 
following study explored the influence of the factors affecting the 
adhesion characteristics when such powder mixtures are fluidised 
for inhalation. 
These factors include: 
3.4.1 The effect of carrier surface properties 
The surface properties of a carrier play an important role in the 
adhesion tendency of drug particles (Staniforth et al, 1982). 
Carriers which possess a more porous, rough surface could form 
stronger interparticulate forces due to the entrapment of the fine 
drug particles within the surface clefts and indentations. In dry 
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powder aerosols the penetration of the drug particles into the lungs 
is largely influenced by the strength of the interparticulate forces. 
The stronger the forces the lower the redispersion of the drug from 
the carrier surface. Therefore, a range of carriers with different 
surface textures were selected to study the influence of the surface 
properties on the inspirable characteristics of a cloud. 
Particle engineering, which can be defined as the physical or 
chemical modification of a solid to produce a desired physico- 
mechanical properties, may also be utilized to produce carriers with 
different surface properties. Crystallization is the most useful 
method which yields a wide variety of physical forms with identical 
chemical properties. Therefore, an attempt was made to produce 
lactose particles with a surface smoother than that of the 
commercially available lactose. 
Materials and methods 
1. Crystallization of lactose 
Lactose monohydrate was crystallized under controlled conditions 
so as to favour the production of crystals having low degree of 
rugosity. A saturated solution of lactose in water (2: 1) was 
prepared. A water immiscible organic solvent hexane (reagent 
grade) was added in a proportion 1.5 times the volume of the 
saturated solution. The mixture was agitated at 500 rpm with a 
paddle. Acetone (reagent grade) which is miscible with both 
solvents was then added to the mixture in a proportion which was 
5% of the total volume of the other solvents. The partially miscible 
mixture formed was stirred for 8 to 12 hours during which lactose 
crystals were produced. After crystal growth, the particles were 
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filtered and washed with acetone to remove excess mother liquor. 
The particles were then washed with 60% ethanol/water mixture to 
reduce the quantity of the very fine particles present and with pure 
ethanol to facilitate quick drying. The crystals were dried in an 
oven at 100°C and stored in a vacuum desiccator over silica gel. 
2. The powder mixtures 
Blends of salbutamol sulphate (2.8jzm MMD) and glass beads, 
milled glass, regular lactose, spray dried lactose or recrystallized 
lactose, prepared in a ratio of 1: 67.5, were investigated. 
3. Flow rate 
Experiments were conducted at air flow rates of 60 and 1501/min. 
Results and discussion 
1. Scanning electron microscopy 
Representative photomicrographs of the surface details of glass 
beads, milled glass, regular lactose and spray dried lactose are 
shown in Figure 3.4. A marked difference in the surface 
morphology of the different carriers is illustrated. The spherical 
glass beads possess the smoothest surface. Milling the glass beads 
produced regularly shaped particles with some surface 
discontinuities. However, this surface appears relatively smooth 
and non-reentrant in comparison with regular lactose. The spray 
dried lactose showed some fairly large surface cavities. However, 
the crystallisation of lactose produced particles Of Smooth 
appearance with no pores or irregularities when compared to 
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regular lactose (Figure 3.5). 
The surface roughness of the carriers increased in the order: 
glass beads <milled glass < recrystallised lactose < regular 
lactose < spray dried lactose. 
2. Surface roughness (rugosity) 
The rugosity values for the different lactose carriers is given in 
Table 3.6. 
The rugosity increased in the order: 
recrystallised lactose < regular lactose < spray dried lactose. 
3. The effect of surface properties on the characteristics of an 
inspirable cloud 
The results given in Figures 3.6 and 3.7 show that the change in the 
surface properties of the carrier has a great influence on the 
pattern of drug deposition. 
The influence of the air flow rate on drug deposition with all 
carriers is also illustrated. At 1501/min higher deposition on stages 
3 to 7 was observed. Additionally, emptying the inhaler was more 
efficient at this flow rate compared to that at 60 1/min. 
A great variation in the amount of drug retained in the inhaler was 
also observed between the different carriers. When the spherical 
glass beads were used as a model carrier in the powder mixture, the 
amount of drug retained in the inhaler was significantly higher 
compared with the other carriers investigated. This phenomenon 
can be explained in terms of the difference in surface morphology. 
The adhesion of the fine drug particles to the glass beads which 
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Table 3.6 Surface roughness (rugosity) of the carriers 
Carrier Rugosity 
Regular lactose 2.3 
Spray dried lactose 2.6 
Recrystallized lactose 1.2 
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particles (Figure 3.8), results in very weak adhesive bonds. 
Therefore, de-mixing is expected to occur with the minimum 
generated force under normal handling. The detached drug 
particles then tend to impact onto the walls of the inhaler as a 
result of their cohesiveness. However, when milled glass was used, 
the amount of drug retained in the inhaler was smaller since the 
mixture was less prone to segregation due to the relatively rough 
surface of the milled glass (Figure 3.8). Furthermore, when 
regular and spray dried lactose were used as carriers, a much lower 
fraction was retained in'the inhaler indicating that a more stable 
powder mixture was formed. Although this seems to be an 
advantage as more drug can be delivered to the patient, the results 
show that most of the drug was recovered from the preseparator 
stage and a much lower fraction was deposited on stages 3 to 7. 
For example, at an air flow of 150 1/min, 55% of the drug was 
retained in the preseparator and 17% deposited on stages 3 to 7. 
However, when glass beads and milled glass were used as carriers 
lower drug deposition in the preseparator stage was observed with 
a relatively higher respirable fraction (30%). 
These results indicate that the smooth surfaces of both the glass 
beads and the milled glass allow the drug particles to free 
themselves from the carrier surface more easily. In comparison, the 
relatively rough surfaces of both regular and spray dried lactose 
limited the separation of the drug particles from the carrier surface 
upon fluidisation as a result of the high interparticle forces within 
these mixtures.. However, although the photomicrographs (Figure 
3.4) show that the spray dried lactose possess a'rougher surface 
than the regular lactose, the respirable fraction obtained was 
comparable to that of regular lactose. This can be explained by 
168 
.ý 
Effect of surface properties of different carriers on the characteristics of 
an inspirable cloud at different airflow rates 
% Drug deposited at various stages at air flow rate of 60 I/min 
100 $ Glass beads 60um 
90 ® Milled glass 63-90um 
80- 77 Regular lactose 63-90um Q Spray dried lactose 63-90um 
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examining the photomicrographs of the mixtures (Figure 3.8). 
These show that the drug particles were distributed on the external 
surface of the spray dried lactose and only very few particles 
appeared to be adsorbed into the surface cavities. 
The above results suggest that a weak association between the drug 
and the carrier in powder mixtures for inhalation is beneficial. The 
fine drug particles can redisperse themselves more easily from the 
carrier surface and penetrate deep into the lungs. However, neither 
the regular lactose nor the spray dried lactose provide an ideal 
surface properties. 
Recrystallized lactose with lower rugosity than both regular and 
spray dried lactose resulted in a marked increase in the respirable 
fraction when used as the carrier (Figure 3.9,3.10). This increase 
was accompanied by a decrease in the amount of drug deposited in 
the preseparator stage, suggesting that the association of the fine 
drug particles with the carrier surface was reduced. The 
photomicrographs of the mixture formed by mixing the fine drug 
particles with the recrystallized lactose (Fig3.10) show that the fine 
particles were distributed on the carrier surface as a monolayer and 
no substantial agglomerates were formed. The increase in the 
respirable fraction was more pronounced at a flow rate of 601/min, 
where an increase from 4% with regular lactose to 23% with 
recrystallized lactose was observed. In comparison, at 1501/min the 
respirable fraction was-only increased from 17% to 42% for the 
regular and recrystallized lactose, respectively. 
Therefore, modifying the surface of the lactose resulted in a fewer 
or weaker sites of adhesion. Moreover, the smooth surface 
i 
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Effect of surface properties of regular lactose and recrystallised lactose 
on the characteristics of an inspirable cloud at different airflow rates 



























% Drug deposited at various stages at air flow of 1501/min 












Uävýýer rIuD IJdIawI výayvý výG Jiä9@S 3-% 
Fig 3.10 
172 
Device Preseparator Stages 0-2 Stages 3-7 
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Fig 3.11 Scanning electron micrographs of 
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A mixture of salbutamol sulphate and 
recrystallized lactose 
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Fig 3.11 Scanning electron micrographs of 
minimized the effect of surface asperities which could prevent drug 
particle detachment by mechanical interlocking. 
However, although the release of the adherent particles is more 
likely to occur with the smooth surface carrier, the amount of drug 
retained in the inhaler was similar to that when regular lactose was 
used. This indicates that the adhesion was sufficiently strong to 
prevent drug particle detachment under low forces but allowed a 
high proportion of the particles to separate during "inhalation". 
Therefore, the recrystallized lactose provided the ideal surface 
properties since a low amount of the drug was retained in the 
inhaler and an efficient redispersion of the drug particles was 
achieved during "inhalation". 
Additionally, the improved efficiency at low air speeds suggests that 
this formulation can be effective even in patients with severe 
asthma and in children who cannot achieve high inspiratory flow 
rates. 
This invention provided a carrier which is inert, soluble, non-toxic 
and sufficiently free flowing suitable for use in powder aerosols. 
3.4.2 The effect of particle size of the drug 
In dry powder aerosols a respirable particle size of the drug i. e 
<514m must be used in the formulation. Therefore, to study the 
influence of the particle size of the drug on the inspirable 
characteristics of an aerosol cloud the range of sizes that can be 
employed is very narrow. However, an attempt was made to 
produce drug particles with different mass median diameter. 
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Materials and methods 
1. Micronization of salbutamol sulphate 
A batch of salbutamol sulphate was milled under conditions which 
differed from those described in Section 2.2.1 by micronizing at a 
powder feed rate of 5g/min and an air pressure of 3.5 bar. 
An electronphotomicrograph of the micronized drug is shown in 
Figure 3.12. 
2. Powder mixtures 
The micronized batch of salbutamol sulphate obtained by milling 
under the conditions described in section 2.2.1 (Batch 1) and the 
above batch (Batch 2) were mixed with lactose of 63-90µm size 
fraction in a ratio of 1: 67.5. 
3. Flow rates 
Experiments were conducted at air flow rates of 60 and 1501/min. 
Results and discussion 
1. Particle size of salbutamol. sulphate 
The mass median diameter of Batch 1 of the micronized 
salbutamol sulphate was 2.8µm with a geometric standard deviation 
of 1.3 and for Batch 2,3.5µm with a geometric standard deviation 
of 1.4. 
The size distribution is shown in Figure 3.13. 
2. The effect of drug particle size on the characteristics of an 
inspirable cloud 
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with a different mass median diameter in the powder mixture had 
no significant influence on the pattern of drug deposition. This 
disagrees with previous investigations if the results are to be 
interpreted in terms of the effect of the adherent particle size on 
the adhesion characteristics. 
The effect of the adherent size on the degree of adhesion was 
studied by several workers using different adhesive systems and 
techniques (Corn and Stein 1965, Kulvanich and Stewart 1987a, 1ý. An 
increase in the adhesive force was observed with a reduction in the 
particle size. 
However, the most relevant study to the present work is the one 
carried out by Corn and Stein (1965) who showed that the removal 
efficiency of a particle exposed to a bulk air stream velocity 
decreased with the reduction in particle size. This was explained by 
the fact that these small particles sink deeper into the boundary 
layer at the surface, until they are out of the range of the main 
stream eddies which could dislodge them. Therefore, once the 
particle is engulfed in the laminar sublayer, it requires a higher 
bulk air stream velocity to thin this layer in order to reach this 
particle. 
In the current study, the assessment of the powder mixtures 
containing adherent particles of different sizes showed no increase 
in the respirable fraction when the larger drug particles were used, 
even at flow rates of 150 1/min. This reflects the fact that the 
variation in the adhesive forces was not significant for the two 
particle sizes used. Larger differences in the size distributions 
might have given different results. However, milling the powder to 
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Table 3.7 Effect of drug size on the pattern of drug deposition at various flow rates 
Air flow rate Device Preseparator Stages 0-2 Stages 3-7 
(1/min) 
Drug size 2.8um 
60 13.2 69.0 1.3 4.1 
150 15.2 51.9 1.3 15.6 
Drug size 3. Sum 
60 143 57.4 1.3 4.8 
150 12.6 50.6 1.2 14.4 
a, rýýr 
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a mass median diameter of less than 2.8pm is difficult. Moreover, 
for the particles to penetrate into the lung, their size should not 
exceed 5pm. Therefore, this experiment was limited by the range 
of sizes that can be produced and used. 
3.4.3 Effect of the concentration of drug powder 
The concentration of the drug in the powder mixture was varied 
using different drug to carrier ratios. 
The maximum salbutamol sulphate concentration that could be 
packed on the carrier surface was theoretically estimated by 
assuming that the drug particles formed a close-packed monolayer. 
The amount of drug can be calculated from the following equation 
(Jones and Pilpel 1965): 
The amount of drug =2 7r d (D+d)2/ITD3 
where D and d are the diameters of the carrier and drug, 
respectively. 
Materials and methods 
1. Powder mixtures 
Blends of salbutamol sulphate (2.8µm) and lactose in the size 
fractions of 63-90µm and <20pm were prepared in ratios of 1: 135, 
1: 67.5and 1: 33.7. A ratio of 1: 1 and 1: 64 were prepared when the 
salbutamol was mixed with the carrier sizes of <20µm and 63- 
90µm, respectively. The later ratios were required to saturate the 
carrier surface with the drug particles. 
The use of a micronized drug without any carrier added to the 
formulation was also investigated. 
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2. now rate 
Experiments were conducted at flow rates of 60 and 1501/min. 
Results and discussion 
The deposition behaviour of a drug from powder mixtures 
containing different drug concentrations is compared in Figures 
3.14 to 3.17. A similar pattern of deposition was observed at the 
two flow rates employed. The amount of the drug retained in the 
inhaler was inversely related to the proportion of lactose in the 
powder mix and it was greatest when salbutamol was used without 
any carrier. A lower deposition in the preseparator stage and a 
noticeable rise in the respirable fraction were observed as the 
proportion of lactose in the mix was reduced particularly at an air 
flow of 1501/min. 
No significant increase in the respirable fraction was observed 
when a high drug concentration was used at a flow rate of 601/min. 
This indicates that the separation force was not sufficient to 
overcome the interparticulate adhesive forces. However, the 
amount of the drug deposited on stages 3 to 7 was higher when the 
fine carrier (<20, m) was used. This was attributed to the effect of 
the carrier size on the adhesion characteristics (see Section 3.4.9). 
Additionally, when the fine carrier was used in a 1: 1 ratio, a high 
percentage of the drug was retained in the preseparator at an air 
flow of 601/min. This might be explained by the formation of 
agglomerates at, this, concentration; the surface available for 
adhesion being not sufficient for the dispersion of the fine drug 
particle and the low air speed was ' not' enough to break such 
agglomerates. However, as the proportion of lactose was increased 
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Effect of drug concentration in the powder mix on the characteristics of 
an inspirable cloud using a carrier size of 63-90um at different airflow 
rates 
% Drug deposited at various stages at air flow of 60 Umin using carrier size of 63.90um. 
100- 13 Salbutamol 
90 Salbutamol: Iactose 1: 1 
80 ® Salbutamol: lactose 1: 33.75 
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Device Preseperator Stages 0-2 Stages 3-7 
Effect of drug concentration in the powder mix on the characteristics of 
an inspirable cloud using a carrier size of <20um at different airflow 
rates 
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in the mix, more surface was available for particle distribution and 
looser or fewer agglomerates were formed. 
No significant variation in the fraction deposited on stages 0 to 2 
was observed with the different concentrations of the drug 
employed. However, more drug was recovered from these stages 
when a fine carrier was used since some of the lactose particles 
were in a size range comparable to that of the drug particles, thus 
forming aggregates. 
The results show that the addition of lactose to the formulation 
improved emptying of the inhaler, thus more drug was made 
available for "inhalation". This has been reported by Bell et al 
(1971) who demonstrated the extensive coating of the interior walls 
of a capsule with the drug particles in the absence of a coarse 
carrier; they suggested the addition of a flow aid in any proportion. 
However, the results of this study suggest that the lactose cannot be 
added in any proportion since increasing the amount of lactose in 
the formulation resulted in a reduction in the respirable dose. 
Thus, when lactose is added, a compromise between powder 
fluidisation and lung penetration must be taken into consideration. 
The increase in the respirable fraction at the higher drug 
concentrations can be explained in terms of adhesion of the drug to 
the carrier surface. Figure 3.18 shows the photomicrographs of the 
ordered mixtures formed at the different concentrations of the drug 
employed. The tendency of the adherent drug particles to form 
particle layers increased with the concentration of the drug. 
Although the amount of drug which could be accommodated on the 
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Fig 3.18 Scanning electron micrographs of mixtures of different drug to carrier ratios 











Fig 3.18 Scanning electron micrographs of mixtures of different drug to carrier ratios 
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carrier surface as a monolayer was theoretically estimated as 1: 6.4 
drug to carrier ratio for a carrier size of 63.90µm, particle layers 
were formed well below this value (Figure 3.18). 
Therefore, the calculation of a monolayer produced an 
overestimate of the amount of particles covering the carrier 
surface. 
Additionally, the particle layer formation observed at the high drug 
concentration occurred despite the availability of a free space on 
the carrier surface. These observations are supported by Hersey 
(1975) who suggested that some areas of the carrier surface are 
devoid of binding sites and some sites are stronger than others. 
Therefore, due to the limited number of active sites, as the 
concentration of the drug increases, the excess drug particles which 
are not capable of forming strong bonds with the carrier will either 
form weaker association or remain free in the bulk mixture. 
Another possible explanation is that a multiple detachment of drug 
particles might occur either due to a collision effect or a particle 
layer formation. 
As the concentration of the drug in a mixture increases, the 
interparticle distance decreases with a greater chance for particle 
collisions to-occur. The collision effect results from the 
impingement of the detached particles with neighbouring particles 
which were in their path as they leave the carrier. Particles detach 
from the carrier surface in a way which depends on the direction of 
the forces acting on the particle. They might be removed by sliding 
or rolling off the carrier. Consequently they tend to collide with 
other particles resulting in multiple detachment. 
Furthermore, a rough surface of the carrier facilitates the formation 
186 
of particle layers. Fine powders tend to fill up the surface 
irregularities in agglomerates rather than in a particulate manner. 
Therefore, multiple detachment-in the form of particle: layers might 
occur if the binding force between the inner particles in contact 
with the carrier surface is less than the external force applied. 
These particle layers then break'up'into single particles at the high 
air speeds. 
The results are at variance with the findings of Chowhan and Linn 
(1978) and Chowhan and Amero (1977) who reported that an 
increase in the lactose proportion in the formulation of powder 
aerosols would result in an increase in the respirable fraction. 
However, their studies were carried out at an air flow of 291/min 
which may have been inadequate for complete fluidisation of the 
powder. Here the influence of increasing the proportion of lactose 
in their powder mix would have overcome problems in powder 
flow. Consequently the possibility of drug penetration into the 
respiratory tract would have increased as a result of dispensing 
higher drug doses rather than an efficient redispersion of the drug 
particles from the carrier surface. 
Therefore, it can be concluded from this study that the higher the 
drug concentration in the formulation, the more efficient is the 
drug delivery to the lungs. However, this is only true at high flow 
rates since 
'a 
large force is required to breakup the aggregates and 
agglomerates. 
3.4.4 The effect of a ternary component in the mix 
It has been observed by Lai and Hersey (1979) and Staniforth and 
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Rees (1982) that the presence of a ternary component might 
stabilize or de-stabilize the powder mixture. The addition of 
magnesium stearate and colloidal silicas was reported to reduce the 
mechanical stability. Therefore in the following study, although dry 
powder aerosols are usually comprised of the drug and the carrier 
only, the effect of adding these two materials to the powder mix 
was investigated. 
Materials and methods 
1. Powder mixtures 
The ternary mixtures were prepared by tumbling lactose in the size 
range of 63-901, m with 1.5% magnesium stearate or 1.5% "Aerosil" 
200 for three days in a glass jar using a roller mill. These were then 
mixed with micronized salbutamol sulphate (2.8)im MMD)in a 
ratio of 1: 67.5. 
2. Flow rate 
The aerosol cloud was generated at air flow rates of 60 and 150 
1/min. 
Results and discussion 
The drug deposition behaviour of the powder mixtures containing 
magnesium stearate or "Aerosil" as the ternary component is shown 
in Figures 3.19 and 3.20. The pattern of deposition is compared 
with that obtained for a regular lactose. 
When lactose tumbled with either magnesium stearate or "Aerosil" 
was used, a slightly higher amount of the drug was retained in the 
inhaler in comparison with regular lactose. As for the deposition on 
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Effect of the presence of ternary component in the powder mix on the 
characteristics of an inspirable cloud at different airflow rates , 
% Drug deposited at various stages at air flow rate of 60 Ilmin 
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the other stages, the percentage of the drug recovered from the 
preseparator stage was significantly reduced when either 
magnesium stearate or "Aerosil" was present in the mixture. This 
was accompanied by an apparent increase in the respirable 
fraction. For instance, at an air flow of 1501/min , the amount of 
drug retained in the preseparator decreased from 50% to 35% and 
the respirable fraction increased from 17% to 34% with regular 
lactose and lactose tumbled with magnesium stearate, respectively. 
When "Aerosil" was used, the respirable fraction was slightly lower 
(30%). 
A similar pattern of deposition was observed at 601/min. However, 
only 14% of the drug was recovered from stages 3 to 7. 
These results indicate. that the characteristics of an inspirable cloud 
are highly influenced by the presence of a ternary component. 
These components may act by binding to the strong active sites 
and/or by filling the surface irregularities during the tumbling 
process. Another possible explanation is that these components act 
by stripping the drug particles from the carrier surface as described 
previously by Lai and Hersey (1979). The electrostatic behaviour 
of these materials in relation to the other components of the 
powder mixture might also contribute to the reduction of the 
mechanical stability of these mixtures (see Section 3.5.3). 
Additionally, these adjuvents are lubricants with a large surface 
area and tend to coat the drug particles with a lubricant film 
thereby reducing their adhesion tendency to the carrier surface. 
Therefore, it can be concluded that the extent of association 
between the drug and the carrier was altered in the ternary 
mixtures by one or more of the above mechanisms. This resulted in 
a more efficient redispersion of the drug particles. 
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However, the effect of adding another component to the mixture is 
difficult to predict and is complicated by the behaviour of the 
powder constituents in relation to each other. Thus, three 
possibilities exist: the mechanical stability of the powder mixture 
may be enhanced, reduced or unaffected by the presence of other 
adjuvents. 
Hence, although addition of both magnesium stearate and "Aerosil" 
resulted in a more highly respirable cloud from the powder 
mixtures employed in this study, these two adjuvents may behave 
differently when used with other powder mixture components. 
3.4.5 The effect of carrier size 
The choice of the carrier size in dry powder aerosols is based on 
two main aspects. First, a very large carrier i. e, >20014m, is 
unsuitable as it is difficult for these particles to be carried by the 
inhalation air stream due to gravitational forces. Second, the use of 
very fine carrier particles is undesirable due to the poor flow 
properties of these mixtures which create problems of filling and 
dispensing. Therefore, the carrier size employed in the formulation 
of powder aerosols is mainly in the range of 30-90µm, with a very 
limited fraction of finer and coarser particles. In the following 
investigation a range of carrier sizes from <'10µm and up to 180µm 
were employed to study the influence of carrier size on the 
inspirable characteristics of an aerosol cloud. 
Materials and methods 
1. The powder mixtures 
Blends of salbutamol sulphate (2.8µm MMD) and regular lactose in 
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size fractions of 125-180µm, 63-90µm, 20-40µm, <20µm and < 10µm 
were prepared in a ratio of 1: 67.5. Mixtures of the drug and 
unclassified lactose were also investigated. 
2. Flow rate. 
The aerosol cloud was generated at air flow rates of 60,100,150 and 
2001/min. 
Results and discussion 
The influence of the flow rate on drug deposition on stages 3 to 7 
with all the carrier sizes employed is shown in Figure 3.21. 
The results show that an increase in the air flow rate resulted in an 
increase in the respirable fraction with all the carrier sizes used. 
For instance, at an air flow of 200 1/min and a carrier size of 
< 10µm, 47% of the drug was deposited on stages 3 to 7 in 
comparison with 17% at a flow of 601/min. 
The influence of the carrier size and flow rate on the fractional 
deposition of the drug is given in Table 3.8. 
The data indicate that emptying the inhaler was more efficient at 
the higher flow rates and that more drug was retained when a fine 
carrier was used. The latter can be explained by the high 
cohesiveness of these powders as illustrated by their tensile 
strength values (Figure 3.1). 
Drug deposition on the other stages was found to be highly 
dependent on the carrier size. When a coarse carrier was used, a 
high fraction of the drug was recovered from the preseparator stage 
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Fig 3.21 -Effect of airflow rate on the amount of drug deposited on stages 3. 
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Table 3.8 The percentage of dose deposited at various stages 
Flow rate Device Preseparator Stages 0-2 Stages 3-7 
Vmin > 10um 5-10um < 5um 
Carrier size <10um 
200 14.2 7.1 15.6 47.7 
150 18.5 7.2 23.9 36.0 
100 26.2 17.1 11.1 38.9 
60 29.5 26.2 9.2 16.9 
Carrier size <20um 
200 13.7 9.2 14.7 38.4 
150 22.8 9.1 16.6 26.0 
100 19.8 20.0 19.3 29.5 
60 27.2 40.7 10.9 12.7 
Carrier size 20-40um 
200 17.7 26.3 2.3 23.0 
150 17.6 22.0 2.3 27.0 
100 21.2 32.8 2.9 14.5 
60 20.1 46.0 2.1 6.4 
Carrier size 63-90um 
200 14.5 50.2 1.2 22.0 
150 15.2 51.9 1.3 15.6 
100 15.1 61.0 1.3 15.2 
60 13.2 69.0 1.3 4.1 
Carrier size 125-180um 
200 13.0 55.2 2.0 22.5 
150 14.3 64.5 1.5 15.4 
100 '- 15.6' 73.9 0.9 7.5 
60 10.3 82.2 0.5 4.0 
Unclassified lactose 
200 
, .. -19.3. 
22.0 8.4 "27.7 150 19.9 22.4 8.5 26.4 
100 -'. 19.9 26.4 11.9 21.5 
60 20.3 46.0 10.9 13,2 
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low drug deposition in the preseparator and the high fraction 
deposited on stages 3 to 7 indicate that the interparticle adhesion 
forces were reduced. These effects were observed at all flow rates 
showing that the detachment of the fine drug particles from the 
surface of the carrier decreases as the particle size increases. This 
can be explained by examining the electron photomicrographs 
(Fig3.22) which indicate that the coarse lactose particles provide 
stronger adherence sites due to the more surface discontinuities 
shown by the increased surface roughness. This agrees with the 
findings of Staniforth et al (1982) who pointed out that the 
interparticle adhesion forces are much higher in ordered mixes 
based on large carrier particles. Smaller carriers release a higher 
fraction of the adhering particles due to the fewer strong adherence, ' 
sites as can be seen from the photomicrograph (Figure 3.22). 
Another possible explanation is that the aerosol cloud comprising 
fine particles is more likely to be completely entrained by the air 
stream, thus responding to its acceleration and deceleration. 
Consequently the dislodgement of the fine drug particles from the 
carrier surface is more efficient. In comparison, the entrainment of 
a cloud comprising a coarser carrier by the air stream depends on 
the particle size distribution of the cloud i. e. the coarser the 
particles the lower the degree of entrainment. 
As for the deposition on stages 0 to 2: when a coarse carrier was 
used, all the particles in the mixture were either larger or smaller 
than the cut-off size of these stages. Therefore, there can be 
virtually no material within this size range, unless formed by drug 
agglomerates. The small amount of deposition given in Table 3.8 
195 
Fig 3.22 Scanning electron micrographs showing the 
surface details of 
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Fig 3.22 Scanning electron micrographs showing the 
stirf. ºcc c etiils of 
indicates that any such agglomerates would have been broken up 
during mixing by the mechanical action of the large particles. In 
formulations comprising a small carrier size, many particles were 
within the size range of these stages, therefore a high percentage of 
the drug was recovered as a coarse material, either as agglomerates 
or as drug adsorbed on the surface of the fine carrier. 
When unclassified lactose was used in the formulation, 
intermediate results were obtained. For example, at an air flow of 
1501/min the amount of drug deposited on stages 3 to 7 was 26.4%. 
This is lower than that achieved by using the fine carrier (36.0%), 
but higher than that when the coarse carrier was used (15.4%). In 
such a mixture comprising coarse and fine particles, it is probable 
that the small particles release more of the adhering particles than 
the coarse ones, therefore contributing more to the effective 
delivery of the drug to the lungs. 
Bell et al (1971) reported that the optimum carrier size in dry 
powder aerosols is in the range of 70-100µm, and that the use of 
finer or coarser carriers markedly reduces the respirable fraction. 
These observations were obtained with a "Spinhaler" and at airflow 
rates not exceeding 601/min. The use of a fine carrier limited the 
availability of the medicament due to the high retention of the drug 
in the capsule, since a flow rate of s601/min is insufficient for 
complete fluidisation of the powder. The use of coarser carriers 
resulted in an intermittent blocking of the holes drilled in the 
capsule wall, as dispensing occurs through these holes. A carrier 
size of 70-10014m provided optimum flow of the powder and 
avoided the problems observed with the coarser and finer carriers. 
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However, these observations are mainly applicable to the type of 
inhaler they used and the conditions of their experiment. 
Thus, it can be concluded that the choice of the carrier size should 
not be based on the flow properties of the powder. The carrier size 
influences the characteristics of an inspirable cloud mainly by 
affecting the nature of the adhesive forces formed between the 
mixture components. A coarse carrier resulted in poor inspirable 
characteristics of a cloud, whereas a fine carrier was found to 
markedly improve the efficiency of a powder aerosol despite the 
poor flow properties. 
However, if this carrier is to be used on a large industrial scale, 
several technical problems may be encountered. Therefore, the 
potential therapeutic advantages may have to be set against the 
possible production difficulties. 
3.5 Electrostatic properties of powders 
Measurement of electrostatic charges provides useful information 
regarding the behaviour of particles forming the adhesive mix. In 
general, the larger the difference in magnitude of electropositive 
and negative charges of two sets of powder particles, the larger will 
be their mutual attraction. 
Therefore, in dry powder aerosols, since the strength of the adhesive 
forces between the drug and the carrier is one of the major factors 
influencing the characteristics of an inspirable cloud, this 
investigation aimed to determine the sign and magnitude of the 
charge which develop on the powder mixture constituents. 
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3.5.1 Theoretical considerations 
Under normal handling, powders can become charged by contact, 
friction or impact against other surfaces, even in the absence of an 
externally applied electric field. Such charging is known as contact 
electrification or triboelectrification. The simple model of 
triboelectrification can be described by metal-metal contacts. The 
typical energy level diagram for a metal material is illustrated in 
Figure 3.23a. Electrons exist in the material within various energy 
levels up to the outermost level associated with the conduction of 
electrons, i. e. the Fermi level. The work function of a metal is the 
energy difference between the Fermi level and a reference level 
outside the molecule known as the vacuum energy level. On 
contact between metals possessing different work functions, 
electrons are transferred between surfaces until the Fermi levels 
are equal (Figure 3.23b). To reach this state, one material loses 
electrons to become electropositive, whereas the other material 
accepts the electrons thereby becoming electronegative. When the 
two surfaces are semiconductors or insulators, as in most 
pharmaceutical powders, the concept of work function is more 
complex. However, electrostatic charging will occur in a similar 
manner, - although the charge transfer mechanisms are less well 
understood. 
3.5.2 Electrostatic charge measurement 
The specific charge of powders was determined using a Faraday 
well connected to an electrometer (type 610C, Kiethley 
Instruments, Cleveland, USA). 
The Faraday well, shown in Figure 3.24, is a double-walled vessel. 
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The outet wall is grounded and forms an electrical screen which 
prevents stray external charges from affecting the measurement. 
The inner wall is connected to an electrometer which detects the 
voltage built up across a known capacitance. Micronized 
salbutamol sulphate and other materials, which included: regular 
lactose in the size range of 63-90µm and <20pm, spray dried 
lactose (63-90µm), recrystallized lactose (60-90µm), glass beads 
(60µm), milled glass (63-90µm), magnesium stearate (<20µm) and 
"Aerosil" 200 (< 10µm), were tested individually. Powder mixtures 
of, the drug and carriers, lactose and magnesium stearate and 
lactose and "Aerosil" were also tested. 
The experiment was carried out by pouring a known weight of 
powder at a constant rate of approximately 0.5g/sec off a perspex 
or brass chute into the inner container of the Faraday well so that 
the base was uniformly covered. Four replicate determinations 
were made for each sample. Brass and perspex were used since 
different materials produce charges of different signs on the same 
powder depending on their position in the triboelectric series. The 
sign of the charge developed on the powders following contact with 
the walls of the "Rotahaler" was also tested by filling the inhaler 
with few grams of the powder sample and tumbling it to facilitate 
contact electrification. The charge magnitude was not recorded 
since it was not possible to pour the powder from the inhaler at a 
constant rate. 
3.5.3 Results and discussion 
The mean static charges obtained with individual powders are 
shown in Tables 3.9 and 3.10. 
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Most of the powders acquired a positive electrostatic charge in 
contact with a Perspex, whereas following contact with a brass some 
materials acquired either a positive or a negative charge. The 
magnitude of the charge was similar for all types of lactose used, 
however it differed significantly between other materials. Potential 
mutual attractiveness can be demonstrated qualitatively using a 
triboelectric series which is analogous to an electrochemical series 
(Staniforth and Rees, 1982b). Although the triboelectric series is 
specific to the conditions under which powders are tested, such a 
series nevertheless gives a useful indication of the possible 
interaction between different powders as well as a better 
understanding of contributing mechanisms. 
Using the data shown in Tables 3.9 and 3.10, a triboelectric series 
were constructed for powders poured off a Perspex or a brass chute 
(Tables 3.11 and 3.12). "Aerosil" 200 was. found to be most 
electronegative following flow on either Perspex or brass chutes. 
Magnesium stearate was the next most electronegative material 
when contacted with a Perspex, but acquired a positive charge when 
poured off a brass chute. 
The mean static charges for the powder mixtures are given in 
Tables 3.13 and 3.14. The sign and magnitude of the charge were 
dependent upon the constituents forming the adhesive mix and on 
their proportions. Thus the charge measured was a net charge 
acquired by the two components. Since the powder mixtures 
consisted of dissimilar sized particles, the number of rubbing 
contact events between the powders themselves and the powder 
and the surfaces will depend on the particle size distribution and 
unequal charging of the particles will therefore occur. Powders 
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Table 3.9 Mean specific charges of different powders measured after flow on a 
perspex chute. (Values are the mean of four separate determinations f standard 
deviations 
Powder sample Mean specific charge Cg-1%1079 
Regular lactose (63-901, m) + 1.21: t 0.42 
Spray dried lactose (63-90µm) + 3.80±0.31 
Recrystallized lactose (60-90µm) + 1.02±0.03 
Regular lactose (<20µm) + 4.40±0.80 
Glass beads (60pm) + 0.35±0.07 
Milled glass (63-90µm) + 0.25 ± 0.02 
Salbutamol sulphate (<5µm) + 1.55±0.36 
Magnesium stearate (<201im) - 2.42±0.36 
Aerosil 200 (< 10µm) - 51.10±5.90 
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Table 3.10 Mean specific charges of different powders measured rafter flow on a 
brass chute. (Values are the mean of four separate determinations & standard 
deviation 
Powder sample Mean specific charge Cg"1 x10'9 
Regular lactose (63-90µm) - 5.36±0.17 
Spray dried lactose (63-90µm) - 3.50±0.26 
Recrystallized lactose (63-90jºm) - 4.80±0.41 
Regular lactose (<20µm) - 7.40± 1.20 
Glass beads (60µm) + 0.70±0.06 
Milled glass (63-901im) + 1.10±0.10 
Salbutamol sulphate (<5µm) + 5.70±1.80 
Magnesium stearate (<20µm) + 2.30±0.71 
Aerosil 200 (<10µm) - 37.00±3.60 
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Table 3.11 Triboelectric series of different powders flow on a perspex chute 
State Powder 
Electronegative Aerosil 200 
Magnesium stearate 













Table 3.13 Mean specific charges of mixtures of powders measured after flow 
on a perspex chute. (Values are the mean of four separate determinations t 
standard deviation) 
Powder sample Mean specific charge Cg-1 x 10-9 
Regular lactose (63-90, im) + Salbutamol sulphate (<5µ-m) + 
4.52±0.25 
67.5: 1 
Regular lactose (63-90pm) + Salbutamol sulphate (<5µm) + 0.45±0.14 
-1: 1 
Spray dried lactose (63-90µm) + Salbutamol sulphate (<5µm) + 6.60±0.16 
67.5: 1 
Recrystallized lactose (60-90i. m) + Salbutamol sulphate (<5µm) + 4.82±0.06 
675: 1 
Regular lactose (<20p. m) + Salbutamol sulphate (<5pm) + 3.70±0.70 
67.5: 1 
Regular lactose (<20µm) + Salbutamol sulphate (<5µm) + 2.14±0.34 
1: 1 
Regular lactose (63-90µm) + Magnesium stearate (1.5%) " 0.44±0.20 
Regular lactose (63-90µm) +, Aerosil 200 (1.5%) " 12.5±3.10 
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Table 3.14 Mean specific charges of mixtures of powders measured after flow on a 
brass chute. (Values are the mean of four separate determinations ± standard 
deviation 
Powder sample Mean specific charge Cg-1 x 10"9 
Regular lactose (63-90µm) + Salbutamol sulphate (<5µm) + 0.43±0.03 
67.5: 1 
Regular lactose (63-90µm) + Salbutamol sulphate (<5µm) + 1.80±0.09 
1: 1 
Spray dried lactose (63-90µm) + Salbutamol sulphate (<5µm) - 0.80±0.04 
675: 1 
Recrystallized lactose (60-90µm) + Salbutamol sulphate (<5pm) + 0.48±0.10 
675: 1 
Regular lactose (<201, m) + Salbutamol sulphate (<5µm) . 1.40±0.13 
67.5: 1 
Regular lactose (<20µm) + Salbutamol sulphate (<51, m) + 0.60± 0.08 
1: 1 
Regular lactose (63-90µm) + Magnesium stearate (1S%) - 1.10±0.30 
Regular lactose (63-90µm) + Aerosil 200 (1.5%) - 5.60± 1.80 
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Table 3.15 The sign of the charge produced on the surface of different powders 
after now on different materials 
Powder sample Perspex Brass Inhaler 
Lactose ± 
Glass +++ 
Magnesium stearate -++ 
Aerosil 200 -- 
Salbutamol sulphate +++ 
ý. .e -t.., 
 
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having fine particle size distribution are expected to acquire higher 
charge magnitudes due to increased surface area facilitating 
contact electrification. However, the results in Tables 3.9,3.10, 
3.13 and 3.14 underestimate the surface charge density of the fine 
powders due to the formation of agglomerates which reduces direct 
contacts between the powder and the surfaces. 
Table 3.15 shows the sign of the surface charge produced on 
different powders following contact with the walls of the 
"Rotahaler". The charge developed is compared with that obtained 
following contact with perspex or brass. The charge sign acquired 
by the powders was similar to that acquired after contact with brass. 
The above method used for electrostatic charge determination 
produced great variations in the magnitude of charge. This has 
been previously reported by Staniforth and Rees (1982b) who used 
the same technique; variations of up to 50-90% were observed in 
some determinations. In this study, despite these variations the 
data obtained provided useful information about the electrostatic 
behaviour of powders in relation to other surfaces. 
The fact that surfaces produce different charge properties has 
significant implications in the context of mixing and fluidisation. 
The dependence of ordered mix stability on the triboelectric 
properties of the surface with which the powders are in contact has 
been demonstrated by Staniforth and Rees (1982b, c). Since the 
further apart powders with different charge signs are in the series 
the greater is their mutual attraction, the surface charges can be 
optimized to facilitate the formation of ordered mixes with 
desirable adhesive properties. Boschung and Glor (1980) pointed 
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out that the specific charge on different drug and excipient powders 
can be increased or decreased according to the triboelectrification 
conditions. 
The behaviour of some of the powder mixtures used in this study can 
be explained by the electrostatic properties of the constituents. For 
example, the use of lactose tumbled with magnesium stearate 
resulted in a higher respirable fractions which was explained in 
terms of the reduced association between the drug and the carrier. 
The above results indicate that lactose developed a charge opposite 
to that of magnesium stearate during tumbling. Thus magnesium 
stearate would be strongly attracted to the active adherence sites 
on the oppositely charged carrier. When salbutamol sulphate was 
added to the mix, it would have been located at weaker adherence 
sites and the dislodgement from the carrier surface will be 
enhanced. 
The electrostatic phenomenon also explains the high segregation 
tendency observed for powder mixtures containing glass as a model 
carrier. In such a mixture, in addition to the smooth surface 
contribution to the weak adhesive forces, the similar charges 
developed on both the drug and the glass particles played a role in 
facilitating the redispersion of the drug particles. 
This study also demonstrates that by a proper selection of the 
material of the inhaler, similar charges can be produced on the 
powder surfaces upon fluidisation during inhalation. Consequently, 
the segregation of the constituents can be enhanced and more Ky 
efficient drug penetration into the lungs can be achieved. 
Therefore, electrostatic charging can be utilized to produce highly 
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respirable powder mixtures by adjusting the type of charge induced 
on the particles. 
Induction of opposite charges on the constituents will be valuable 
during mixing to produce stable powder mixtures for filling and 
handling, whereas induction of similar charges during inhalation is 
necessary to facilitate efficient redispersion of the fine drug 
particles from the carrier surface. 
3.6 Conclusions 
The factors influencing the adhesion characteristics between the 
drug and the carrier, and the force employed to generate the 
powder cloud were found to highly influence the performance of 
powder inhalation aerosols. 
In these studies, the powder properties and their behaviour in a 
turbulent air stream were investigated. The results demonstrated 
that redispersion of the drug particles can be enhanced by several 
methods. A proper choice of the carrier size, the carrier surface 
properties which facilitate drug particle detachment but resist 
segregation under normal handling and processing, the presence of 
ternary components in the mix, the use of an appropriate 
proportion of the carrier in the mix and controlling the surface 
charge induced on the powder surfaces, all improve the availability 
of the medicament to the lungs. 
However, although the use of ternary components in the mix 
resulted in highly inspirable clouds, the addition of these 
components to powder mixtures for inhalation is undesirable as it is 
not advisable to deliver these foreign particles to the delicate 
tissues of the lungs. 
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The use of a smooth surface carrier seems to be the most 
appropriate method to increase the inspirability of a powder 
aerosol cloud. The use of such a carrier will overcome the problem 
of cohesive powder fluidisation which is a major drawback to the 
use of fine carriers . Additionally, this will limit the proportion of 
the carrier that can penetrate into the lungs. 
These studies also demonstrated that when formulating dry 
powders for inhalation by mixing the fine drug particles with a 
coarser component, the factors affecting the adhesion properties 
can be employed to modify the relationship between the drug and 
the carrier thus improving the efficiency of these aerosols. 
Moreover, the influence of air flow rate demonstrated throughout 
this chapter indicated that with all the formulation variables, 
greater efficiencies were obtained at high flow rates. Therefore, in 
such a dosage form, even if a good formulation is developed, 
generation of deeply inspirable cloud cannot be achieved unless 
combined with both the use of an inhalation device which produces 
high de-aggregation of the powder, and a proper inhalation 
manoeuvre by the patient. 
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Chapter four 
Clinical assessment of a novel powder formulation 
and a newly designed inhalation device 
ý, 
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4.1 Introduction 
The efficiency of dry powder aerosols depends on three major 
factors: the patient, the powder formulation and the inhalation 
device. The patient plays an essential role since redispersion of the 
fine drug particles is limited by the energy available from the 
inspiratory flow. However, controlling the force provided by the 
patient is difficult. Therefore, the development process of a 
powder inhalation product should involve the design of a 
formulation and a delivery device which provides a maximum 
redispersion with minimum effort on the part of the user. 
The in vitro studies in Chapter 3 suggest that this approach is 
possible to achieve by modifying the relationship between the drug 
and the carrier. The invention of a carrier with low surface rugosity 
provided a formulation which can be redispersed efficiently even at 
low air flow rates. 
The construction of the inhaler can also provide efficient de- 
aggregation of the powder mixture if high levels of turbulence are 
attained. The design of the inhaler described in Chapter 3 has an 
additional advantage of low resistance to air flow, therefore 
patients can achieve high inspiratory flow rates with minimum 
exertion. 
However, the respiratory tract is a system of branching tubes of 
progressively decreasing size. This complexity acts as a barrier to 
the penetration of drug particles and none of the in vitro 
experiments can predict the exact behaviour of the aerosol cloud 
once inhaled by human lungs. Therefore, preliminary in vitro 
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findings should be followed by in vivo evaluation of the developed 
inhalation products. 
For inhaled products, the best method which describes the fate of 
the inhaled particles is gamma-scintigraphy. However, labelling 
micronized drug particles has not yet been achieved due to 
technical reasons. Physical labelling of the particles as described by 
Vidgren et al (1987b)and Newman et al (1989) alter the physical 
properties of micronized particles. Therefore the latter technique 
can not be applied to the novel formulation since the inspirable 
characteristics of this formulation are highly dependent on the 
relationship between the drug and the carrier. Therefore, since the 
model drug employed throughout this study is a bronchodilator, 
one of the methods which can be applied to detect the penetration 
of the drug particles into the lungs is by assessing the lung function 
before and after administration of the medicament. 
The commonly accepted criteria for a positive bronchodilator 
response is an improvement in lung functions. Lung functions can 
be described in the following way (Figure 4.1): the volume of gas in 
the lungs at the end of a normal exhalation during quiet breathing 
is termed the functional residual capacity (FRC). The volume of 
air inhaled or exhaled with each breath during quiet breathing is 
the tidal volume (TV). The maximum volume of air that can be 
drawn into the lungs from FRC is the inspiratory capacity (IC), 
whereas the maximum volume that can be exhaled from FRC is the 
expiratory reserve volume (ERV). The volume of gas in the lungs 
after a maximum inspiration is termed the total lung capacity 
(TLC). The vital capacity (VC) is the maximum volume that can 





Fig 4.1 ' Lüng function spirogram 
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The volume of gas remaining in the lung after a maximum 
expiratory effort is the residual volume (RV). 
The gas volume moving into and out of the lungs is commonly 
measured in the laboratory using a closed circuit spirometer. 
The rate of air flow or the volume inhaled or exhaled over specific 
time intervals serve as indirect measure of the flow resistive 
properties of the airways. In measuring a forced expiratory vital 
capacity, the patient takes a full inspiration to total lung capacity 
followed by a maximum, rapid, forceful exhalation into a 
spirometer. 
The measurements require the patient to breathe with his nose 
clipped. The volume exhaled in the first second of expiratory 
manoeuvre from total lung capacity is a forced expiratory volume in 
one second (FEV1). Figure 4.2 shows typical spirometric trace of 
expiratory volume- time curve. 
FEV 1 reflects air flow resistance in the large airways as limitation 
of expiratory flow rates occur in these airways which become 
constricted by increasing the expiratory effort. Other 
measurements characterizing small airway can be performed. 
Using an instrument which measures flow and volume 
simultaneously, it is possible to draw a flow-volume curve as shown 
in Figure 4.3, which displays the instantaneous air flow rate as a 
function of lung volume. 
The vital capacity delivered from total lung capacity (TLC) to 
residual volume (RV) is associated with a reduction in flow towards 
residual volume. In the latter half of the exhalation (Figure 4.3) 
the flow is independent of effort and reflects small airways (52mm) 
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Fig 4.3 Spirometric trace of expiratory 
flow-volume curve 
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(Vmax) at certain percentage of the vital capacity in the latter half 
of the exhalation can be made from the flow-volume curve. 
Since the reversibility of airway obstruction in patients with asthma 
and chronic obstructive pulmonary disease can be detected by 
simple measurements such as FEV1 and Vmax at certain 
percentage of the vital capacity following inhalation of a 
bronchodilator, these two measurements were considered sufficient 
for in vivo evaluation of the developed inhalation products. 
The following study consists of two parts and was designed to: 
(a) Compare the bronchodilator response achieved following 
inhalation of the novel formulation, which was shown to be highly 
respirable in vitro, with that of a commercially available powder 
aerosol formulation. 
(b) Compare the response to the bronchodilator inhaled with a 
newly designed inhaler and a "Rotahaler". 
4.2 Materials and methods 
Since salbutamol was used as a model drug throughout the study, a 
commercially available salbutamol formulation was chosen to 
compare the therapeutic response., A dose of 200µg drug was 
employed as it was difficult to predict the dose which produces 
maximal bronchodilation. - The two formulations were administered 




1. Preparation of the novel powder aerosol formulation 
A powder blend of salbutamol sulphate (2.8µm MMD) and lactose 
was prepared in a ratio of 1: 67 by mixing the micronized drug and 
the recrystallized lactose with a spatula. 13.5±0.68mg of the 
mixture was filled into off-white opaque hard gelatin capsules (size 
3) so that each capsule contained 200µg drug. The content 
uniformity of the capsules was confirmed by the assay of 10 
capsules using the HPLC method described in Section 2.2.2. 
2. A commercial salbutamol formulation 
"Ventolin Rotacaps" 200µg (Allen and Hanbury's Limited, Batch 
Number S7439MA) were employed. To blind the study, the 
capsule contents were transferred into matching hard gelatin 
capsules. The inspirable characteristics of Ventolin were not 
affected by the transfer of the contents as was confirmed by an in 
vitro experiment. 
3. Microbiological test 
Since these powders are intended for inhalation by asthmatic 
patients, it was necessary to ensure that they are free from any 
bacterial contamination since some pathogenic bacteria can 
apparently survive in dry pharmaceutical raw materials. 
Both micronized salbutamol sulphate and recrystallized lactose were 
tested for total viable count. -1 <.. 
A 0.5g samples of each material was dissolved in 5m1 nutrient broth. 
The solutions were incubated for 3-4 hours at 37°C. After 
incubation, triplicate 50,1 samples were plated out onto tryptone 
soya agar plates. The plates were then incubated at 37°C and 
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examined for bacterial growth after 18-24 and 48 hours. 
No microbial growth was detected in either material. 
4.2.2 Inhalation devices 
1. New inhaler 
The inhaler is shown in Figure 4.4. It was made of glass and its 
design is described in Section 3.2. 
Dispensing is performed by inserting the capsule containing the drug 
into the inhaler and turning this end to separate the capsule into 
two halves. The part of the capsule containing the powder drops 
and is retained by a grid inserted at position A. As the patient 
inhales, the powder is dispensed from the capsule into the inhaled 
stream through a nozzle fitted with a grid on the top (position B). 
2. "Rotahaler" (Allen and Hanbury's Limited) 
The design of this inhaler and its mode of use is described in 
section 1.5.3 
4.2.3 Patient selection 
Eleven moderate asthmatic patients (six males and five females) 
volunteered for the study. The mean age of the patients was 38 
years and their clinical condition was stable. The patients 
characteristics are shown in Table 4.1. 
Patients were entered into the study if their forced expiratory 
volume in one second (FEV1) was less than 80% of predicted 
normal value and increased by more than 15% of the initial value 
after inhalation of a brönchodilator. A 15% increase in FEV1 was 
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Fig 4.4 The inhalers used for the in vivo studies (a) the newly designed inhaler 
,( b) the Rotahaler 
222 
respond to a bronchodilators therapy since this exceeds spontaneous 
within-day variations in patients with reversible airway obstruction. 
All patients were non-smokers. 
The study was carried out at King's College Hospital, and the 
protocol was approved by the Hospital Ethical Committee. 
Informed consent was obtained from all subjects. 
4.2.4 Study design 
Patients were enrolled in a four day, double blind cross-over study. 
Patients were randomly allocated to one of the two formulations, so 
that they inhaled either the novel formulation or "Ventolin" using a 
"Rotahaler" in the first two visits, with cross-over of the 
formulations using the new inhaler in visits three and four of the 
study. All bronchodilator therapy was withheld for at least 6 hours 
prior to the study. 
Patients were instructed to inhale as fast as possible. However, the 
peak inspiratory flow rate (PIFR) and the total inspired volume 
were not registered. Some patients inhaled twice from the inhaler 
to ensure complete emptying of the powder. Each inhalation was 
followed by a 10 seconds breath-holding pause. 
The patients had never previously used powder inhalation aerosols 
as a method of treatment except one who used a "Diskhaler" (Allen 
and Hanbury's Ltd). 
Each patient attended the clinic at the same time on the test day. 
The procedure on all four days was the same: the patient was 
allowed to rest for 10 minutes after which baseline measurements 
of lung function as assessed by FEV1 and maximum expiratory 
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volume at 30% of the vital capacity (Vmax30) were recorded using 
a spirometer (Vitalograph). These measurements were made at 
each visit to ensure that the baseline values did not differ by more 
than 15% between the treatment days. Following baseline 
measurements, the subject inhaled one of the randomly allocated 
formulations and subsequently spirometric measurements were 
repeated at 5,10,15 and 30 minutes after inhalation. Each 
measurement was made in triplicate and the results were expressed 
as the increment of each measurement above the individual's pre- 
administration baseline for that day. Four patients were excluded 
after the first two visits as their basal FEV1 and Vmax30 was varied 
by more than 15% from the first two days of the study. Seven 
patients completed the study. 
4.2.5 Determination of the amount of drug retained in the inhalers 
After inhalation, the inhaler and the capsule were rinsed with 20m1 
of methanol and water (65: 35 v/v) and the washings were assayed 
by HPLC as described in Section 2.2.2. The amount of salbutamol 
sulphate recovered was calculated and the percentage of the dose 
delivered was determined in relation to the administered dose. 
4.2.6 Analysis of results 
A paired t-test was used; P<0.05 was considered statistically 
significant. 
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Table 4.1 patient's characteristics 
Patient Sex Age (yrs) Concurrent FEV1 Vmax30 
medication (L) (L) 
1 M 31 82-agonists 1.73 0.42 
corticosteroids 
2 M 24 ß2-agonist 3.73 1.19 
corticosteroid 
3 F 57 B2-agonist 1.33 0.56 
corticosteroids 
4 F 24 B2-agonist 1.37 0.41 
corticosteroids 
Aminophyllin 
5 M 26 ß2-agonist 2.54 1.22 
corticosteroid 
6 F 33 82-agonist 2.34 0.97 
corticosteroid 
7 M; 45 ß2-agonist 2.52 1.41 
corticosteroid 
8 F 32 82-agonist 2.29 1.38 
corticosteroids 




10 F 36 corticosteroids 1.49 0.53 
11 M 63 82-agonist 2.12 0.27 
M: F x=38 2.04 0.78 
6: 5 range: 24-63 ± 0.77 ± 0.46 
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4.3 Results and discussion 
4.3.1 Formulation 
The two formulations were inhaled by 11 patients using a 
"Rotahaler" and 7 patients using the new inhaler. 
The mean changes in FEV1 and Vmax30 after drug inhalation with 
both devices are shown in Figures 4.5 to 4.8. 
I 
The percentage mean increase in FEV1 above the pretreatment 
baseline was significantly greater for the novel formulation (27.5%) 
than for "Ventolin" (21.4%) (P<0.05). However, for Vm u 30, 
although the percent mean increase was higher for the novel 
formulation (36.6%) than "Ventolin" (29.8%), this was not 
statistically significant (P=0.26) due to the large scatter of the 
values around the mean. 
When the new inhaler was employed, no significant difference 
between the therapeutic responses to these two formulations was 
observed (P> 0.05). 
4.3.2 Inhalers 
The present study showed that with regard to clinical effect, the two 
inhalers are comparable. The lung function results obtained with 
both inhalers are illustrated in Figures 4.9 to 4.12. No statistically 
significant difference in the mean increase of FEV1 or Vmax30 was 
demonstrated (P < 0.05). -- 
4.33 4.3.3 The amount of drug retained in the inhalers 
By analysing the amount of drug retained in the inhalers following 
inhalation, it was found that the dose delivered to the patients was r.. 
less than 200µg in the four treatment days and with all subjects. 
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The mean changes in FEV1 following inhalation of the novel 
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The mean changes in Vmax3O following inhalation with the new inhaler 
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This was expected since the fine drug particles tend to adhere to 
the walls of the inhaler and the capsule following contact. 
However, marked variations between individuals and within 
individuals in each visit were observed. The overall dose of 
salbutamol delivered from both formulations and with both 
inhalers differed significantly. 
The actual doses delivered per actuation to each individual patient 
are compared in Figures 4.13 and 4.14. The "Rotahaler" delivered 
a mean dose of 58.9% and 79.3%, whereas the new inhaler 
delivered a mean dose of 28.7% and 46.6% of the novel 
formulation and "Ventolin", respectively. 
These figures also indicate that the mean dose delivered from the 
new formulation was lower than the mean dose delivered from 
"Ventolin" with both inhalers (Figures 4.15 and 4.16). Therefore, 
the subjects participating in the study received very much less of the 
drug on the treatment days where the novel formulation and the 
new inhaler were used than they did when "Ventolin" and the 
"Rotahaler" were used. 
Therefore, it can be concluded that the novel formulation has 
proved to be better than "Ventolin" as judged by FEV1 values and 
equivalent improvement in lung function following the use of the 
new inhaler. 
However, -considering the large variations in the amount of drug 
delivered to each individual patient, it is'not possible by comparing 
the mean FEV1 and Vmax30 of all subjects to confirm whether the 
difference between the two formulations was highly significant or 
whether any difference between the two inhalers exist. Comparing 
the results individually, i. e. for each patient, might give a clearer 
evaluation. 
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A comparison between the actual dose delivered from the new inhaler 
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The percentage increase in FEV1 and Vmax30 from baseline at 5, 
10,15 and 30 minutes for each individual patient is shown in 
Figures 4.17 to 4.24. 
FEV1 values for each patient following administration of either the 
novel formulation or "Ventolin" using the "Rotahaler" are shown in 
Figure 4.17. 
Despite the substantially lower doses of the novel formulation 
delivered to each subject, a higher percentage increase in FEV1 
was observed for 8 patients (1,2,3,4,6,7,9 and 10) whereas only 
three patients were slightly better on "Ventolin". 
For Vmax30 values (Figure 4.18) there was more scatter in the 
results, three patients (8,9, and 10) achieving higher values 
following administration of the novel formulation and three (4,5 
and 7) showing similar response with both formulations. 
Only two patients (2 and 6) achieved higher response following 
inhalation of "Ventolin". Patients 1 and 11 showed no clinical 
response since the increase over baseline value did not exceed 15% 
and values even below the pre-treatment baseline were observed 
for patient 3. 
Figures 4.19 and 4.20 compare the lung function measurements for 
each patient following the use of the new inhaler to deliver the two 
formulations. The results show a similar trend as that observed 
with the "Rotahaler". However the number of patients who showed 
more improvement on the new formulation was less since they 
received a dose lower than that delivered by the "Rotahaler", and 
more patients showed no response to the bronchodilator. Two 
patients (1 and 3) out of seven demonstrated a greater increase in 
FEV1 over the pre-treatment baseline although they received a 
dose half of that of "Ventolin". 
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One patient (9) showed a comparable FEV1 values with both 
formulations although 41% of the dose was delivered when inhaling 
"Ventolin" compared to only 9% with the novel formulation. 
Patient (10) who achieved higher FEV1 values when inhaling 
"Ventolin", showed higher Vmax30 values with the novel 
formulation indicating that more of the drug had penetrated into 
the small airways. 
When comparing the performance of the two inhalers in individual 
patients following inhalation of either the novel formulation or 
"Ventolin" (Figures 4.21 to 4.24), it can be observed that many 
patients achieved either similar or better response. For example, in 
four patients (1,3,10 and 11) the increase in FEV1 over baseline 
values following inhalation of the novel formulation was similar 
with both the new inhaler and the "Rotahaler". One patient (9) 
showed a higher response when using the "Rotahaler". However, 
this response was only 10% higher than that achieved by the new 
inhaler although 51% and 9% of the dose was delivered by the 
"Rotahaler" and the new inhaler, respectively. 
Similar results were observed with Vmax30 measurements. For 
instance, when "Ventolin" was administered by the new inhaler 
three patients showed a higher response (5,10 and 11) and 3 
patients showed a similar response (1,8 and 9), although the 
amount of drug received by each respective patient was less. 
Patient 11, for example, showed an increase in VmaX30 of 233% 
above baseline values when using the new inhaler, compared to an 
increase of 94% when using the "Rotahaler" although a dose of 
52% and 74% was delivered via the new inhaler and the 
"Rotahaler", respectively. 
The above results suggest that although the mean improvement in 
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lung function was not significantly higher for the new inhaler and 
for the novel formulation as assessed by Vmax30, the variation 
between individuals was quite large. Such variations have been 
generally reported by similar studies and are partially due to 
differences in respiratory anatomy and the disease state of the 
patient. 
In the present investigation an additional reason is the wide 
variation in the amount of drug retained in the inhalers following 
inhalation. One cause for these variations is that these two inhalers 
were used for the first time by the subjects participating in the study 
and no previous training was given on the correct use. Moreover, 
the use of a specific inhalation technique was not practiced by the 
patients. For instance, the number of inhalations from the inhaler 
was not standardized, some patients used two consecutive 
inhalations and some inhaled once only. Additionally, there was 
both intra-individual and inter-individual differences in the velocity 
of the inspiratory air flow. The influence of the inhalation 
manoeuvre on lung function has been demonstrated by several 
workers (Groth and Dirksen , 1983; Auty et al, 1987; Richardset al, 
1988; Dolovich et al, 1989 and Pedersen et al, 1990) and found to 
highly affect the performance of a powder inhalation product. 
Therefore, it can be concluded that since the inhalation technique 
was not standardized, comparing the two inhalation devices in the 
present study might not be reliable even if done individually. In a 
study carried out by Vidgren et at (1987) to compare the 
performance of different commercially available inhalers, patients 
were trained to inhale at air flow between 55-701/min. 
However, comparing the results individually illustrates that the 
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novel formulation and the new inhaler may prove to be more 
efficient if the same dose was delivered to the patients during the 
study. For instance, Vmax30, which indicates drug penetration 
into the small airways (: -52mm), was either higher or similar in most 
patients using the new inhaler despite the smaller amount of drug 
inhaled, demonstrating that a deeply and highly inspirable cloud 
can be generated if the dispensing efficiency of the inhaler is 
improved. 
The high retention of the drug in the new inhaler was observed in 
the in vitro experiments (Section 3.3.2), it did not exceed 34%. 
Fractions of up to 92% were retained when the inhaler was used by 
the patients. 
Variations in the amount of drug recovered from the inhaler 
following use by the patient was reported by Vidgren et al (198'kf) 
and was found to be dependent on the inspiratory effort. In one 
investigation a mean retention of 43.8% was observed when 
inhaling from a "Rotahaler" at an air flow of 55-70 1/min. In 
another investigation (Vidgren et al , 1990) where the 
inspiratory 
flow rate was not standardized, 25.8% was recovered from the same 
inhaler indicating that patients inhaled faster. 
The high retention of the drug in the new inhaler was mainly 
attributed to its complicated design compared to that of the 
"Rotahaler". Additionally, the glass material of the inhaler may 
influence the nature of the electrostatic charges induced on the 
powder particles upon fluidisation and hence the electrostatic 
attraction to the walls of the inhaler. 
The length of the inhaler might also affect its emptying efficiency 
since the powder particles travel a longer distance before they 
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Fig 4.17 FEV1 values for each patient following inhalation of either the 
novel formulation or Ventolin using the Rotahaler 
The percentage of the dose delivered to each numbered patient Is indicated by th 
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influence. It was not possible to construct a shorter version of the 
inhaler from glass due to technical difficulties. 
Another contributing factor to the inefficient emptying of the inhaler, 
is failure of the capsule part, which drops during dispensing, to 
rotate upon inhalation and consequently most of the powder 
remains in the capsule. This problem can be attributed to the 
insufficient inspiratory effort which is the only energy source for 
rotation of the capsule. It has been established that the effect of 
the "Rotahaler" is reduced at inspiratory flow rates below 501/min 
(Pedersen 
, 1990). However, 
it is not clear how sensitive is the 
new inhaler to a reduction in inspiratory flow below 601/min and 
it is possible that there is a critical air flow rate below which the 
effect will be reduced. 
These observed problems with the new inhaler suggest that some 
modifications are required to facilitate more efficient emptying. 
However the results of this investigation indicate that the basic 
design of the inhaler offers an advantage of generating a deeply 
inspirable cloud. 
The reason for the higher drug retention in the inhaler observed 
when the novel formulation was used is unclear since a comparable 
fraction of the drug was recovered with both formulations in the in 
vitro experiments. 
4.3.4 Subjective results 
Comments on the sensation and taste of both treatments are 
summarized in Figure 4.25. Some patients verbally reported an 
improvement in their symptoms following the administration of the 
drug particularly the novel formulation and when using the new 
inhaler although their lung function tests showed no difference. 
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Patient acceptability of the inhalers is shown in Figure 4.26. The 
results indicate a high degree of patient acceptability to both 
inhalers which also indicate patient acceptability to this type of 
inhalation delivery system since they were using it for the first time. 
4.4 Conclusions 
This preliminary study showed that the novel formulation with a 
modified carrier was clinically more efficient than "Ventolin" as 
assessed by FEV1 despite the large difference in the dose delivered 
to the patient. However, it failed to confirm whether the new 
inhaler was more effective than the "Rotahaler" in redispersing the 
aerosol cloud. 
The results suggest that modifying the construction of the inhaler to 
improve its dispensing efficiency, while keeping the same principle 
for generating high turbulence, is essential. Additionally, avoiding 
the shortcomings of this study in future work may result in a more 
constructive evaluation of the new inhaler. 
Standardization of the inspiratory manoeuvre is essential and 
patients should train on the correct use of the inhaler prior to the 
study and practice a specific inspiratory flow rate. The number of 
inhalations through the inhaler should also be standardized. 
Moreover, a larger number of patients should be involved since 
seven patients are not sufficient to compare two delivery devices. 
A more suitable design would be an open randomized, cross-over 
study in which more patients are enrolled. Another study design 
which can be used is a cumulative dose response comparison 
between the two formulations with both inhalers. This type of study 
requires a small number of patients all of which must show a 
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response at a certain dose level. Another advantage with this study 
design is that differences in response can be more obvious at 
higher doses. Moreover, an indication of the dose required to 
achieve a maximal response can be established; this could be 
different for both formulations . The formulation requiring a 
smaller dose to achieve a maximal response being the more 
efficient. 
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